Classifications

• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07D—HETEROCYCLIC COMPOUNDS
  • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
  • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
  • C07D471/04—Ortho-condensed systems
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K31/00—Medicinal preparations containing organic active ingredients
  • A61K31/33—Heterocyclic compounds
  • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
  • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
  • A61K31/47—Quinolines; Isoquinolines
  • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K31/00—Medicinal preparations containing organic active ingredients
  • A61K31/33—Heterocyclic compounds
  • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
  • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
  • A61K31/5375—1,4-Oxazines, e.g. morpholine
  • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
  • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P35/00—Antineoplastic agents
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P37/00—Drugs for immunological or allergic disorders
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07D—HETEROCYCLIC COMPOUNDS
  • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
  • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
  • C07D498/04—Ortho-condensed systems
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07D—HETEROCYCLIC COMPOUNDS
  • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
  • C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
  • C07D513/04—Ortho-condensed systems
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07D—HETEROCYCLIC COMPOUNDS
  • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Definitions

• This disclosure features chemical entities (e.g., a compound or a pharmaceutically acceptable salt, and/or hydrate, and/or cocrystal, and/or drug combination of the compound) that modulate (e.g., agonizes or partially agonizes) NLRP3 that are useful, e.g., for treating a condition, disease or disorder in which an increase in NLRP3 signaling may correct a deficiency in innate immune activity that contributes to the pathology and/or symptoms and/or progression and/or treatment refractory state of the condition, disease or disorder (e.g., cancers with low T-cell infiltration) in a subject (e.g., a human).
• This disclosure also features compositions as well as other methods of using and making the same.
• NLRs Nucleotide-binding oligomerization domain-like receptors
• PAMPs pathogen-associated molecular patterns
• endogenous molecules see, e.g., Ting, J. P. Y. et al.,“The NLR gene family: a standard nomenclature,” Immunity, 28(3):285-287, (2008)).
• NLRPs represent a subfamily of NLRs that include a Pyrin domain and are constituted by proteins such as NLRP1, NLRP3, NLRP4, NLRP6, NLRP7, and NLRP12. NLRPs are believed to be involved with the formation of multiprotein complexes termed inflammasomes (see, e.g., Chaput, C. et al,“NOD-like receptors in lung diseases,” Frontiers in Immunology, 4: article 393, (2013)).
• These complexes typically include one or two NLR proteins, the adapter molecule apoptosis associated speck-like containing a CARD domain (ASC) and pro-caspase-l F (see, e.g., Bauemfeind, F and Homung, V.
• ASC adapter molecule apoptosis associated speck-like containing a CARD domain
• pro-caspase-l F see, e.g., Bauemfeind, F and Homung, V.
• inflammasome is formed by the NLRP3 scaffold, the ASC adaptor and pro-caspase-l (see, e.g., Hirota, J. A., et al,“The airway epithelium nucleotide-binding domain and leucine-rich repeat protein 3 inflammasome is activated by urban particulate matter,” Journal of Allergy and Clinical Immunology, 129(4): 11 l6.e6-l 125. e6, (2012)), and its expression is believed to be induced by inflammatory cytokines and TLR agonists in myeloid cells and human bronchial epithelial cells ⁇ Id.).
• IL- I b and IL-18 have potential in the treatment of various types of cancer (see, e.g., Chen, L-C. et al, EMBO Mol Med., 4(12): 1276-1293 (2012) and Tse, B. W-C. et al, PLoS One, 6(9):e2424l (2011)).
• IL-18 has been shown to override resistance to checkpoint inhibitors in colon cancer animal tumor models (see e.g., Ma, Z. et al, Clin. Cancer Res. Jan 11. (2016) DOI: 10.1158/1078-0432.CCR-15- 1655).
• the invention is directed to compounds of Formula (I):
• the invention is also directed to pharmaceutical compositions comprising one or more compounds of the invention.
• the invention is also directed to methods of treating cancer using one or more compounds of the invention.
• the invention also provides processes and intermediates for making the compounds of Formula (I) or pharmaceutically acceptable salts, stereoisomers, tautomers, and solvates thereof.
• the compounds of the invention may be used in therapy.
• the compounds of the invention may be used for the manufacture of a medicament for the treatment of cancer.
• the present invention provides, inter alia, a compound of Formula
• R 1 is, at each occurrence, independently:
• R la is independently H, Ci-6 alkyl substituted with 0 to 6 F, or C3-6 cycloalkyl substituted with 0 to 6 F;
• R 2 is, at each occurrence, independently:
• Y is independently Ci-8 alkylene substituted with from 0 to 4 R e ; and R 6 is, at each occurrence, independently: H, OH, CN, OR a , -C(0)R a ,
• heteroaryl including from 5 to 10 ring atoms, wherein from 1-4 ring atoms are each independently selected from N, N(R f ), O, and S, wherein the heteroaryl is substituted with from 0 to 3 R d ;
• n is independently 0, 1 or 2;
• Y 2 is independently C3-6 cycloalkylene substituted with from 0 to 4 R g , or heterocycloalky lene including from 3-8 ring atoms, wherein from 1-2 ring atoms are each independently selected from N, N(R f ) and O, and wherein the heterocycloalkylene is substituted with from 0 to 4 R g , and
• R 7 is H, OH, -OR a , -C(0)0R a , -NR b R c , -C(0)NR b R k , or heteroaryl including from 5-6 ring atoms, wherein from 1-4 ring atoms are each independently selected from N, N(R f ), O, and S, and wherein the heteroaryl is substituted with from 0 to 4 R g ;
• Z 1 is Ci-3 alkylene substituted with from 0 to 6 F;
• Z 2 is -N(R f )-, -0-, or -S-;
• Z 3 is C2-5 alkylene substituted with from 0 to 6 F;
• R 8 is OH, OR a , -C(0)R a , -C(0)OR a ; -NR b R c , -C(0)NR b R k , or heteroaryl
• R 3 is independently halo or -(C0-3 alkylene)-(5-membered heteroaryl) wherein the heteroaryl includes 1 to 4 ring carbon atoms and 1 to 4 ring heteroatoms are each independently selected from: N, N(R f ), O, and S, and is substituted with from 0 to 3 R g ; provided that when R 3 is furanyl, R 2 is other than C1-4 alkyl;
• R 4 is independently selected from: H, halo, cyano, OH, C1-4 alkoxy, C1-4 haloalkyl, Ci-4 haloalkoxy, -C(0)OH, -C(0)OR a , -NR'R k . -C(0)NR'R k . -SOi- 2 R h , and CM alkyl substituted with from 0 to 2 R e ;
• R a is, at each occurrence, independently:
• (v) -(Co-3 alkylene)-heteroaryl including from 5 to 10 ring atoms, wherein from 1 to 4 ring atoms are each independently selected from N, N(R f ), O, and S, wherein the heteroaryl is substituted with from 0 to 3 R d ;
• R b is, at each occurrence, independently H or R a ;
• R c is, at each occurrence, independently selected from: H, -C(0)R a , -C(0)OR a , -C(0)NR ) R k , -S(0)i-2R h , Ci-6 alkyl substituted with from 0 to 2 R e ,
• R b and R c together with the nitrogen atom to which each is attached form heterocyclyl including from 3 to 10 ring atoms, wherein from 1 to 3 ring atoms are each independently selected fromN(R f ), O, and S, and wherein the heterocyclyl is substituted with from 0 to 4 R g ;
• R d is, at each occurrence, independently selected from: halo, OH, cyano,
• R e is, at each occurrence, independently selected from: halo, OH, cyano,
• R f is, at each occurrence, independently selected from: H, OH, C1-4 alkyl,
• R g is, at each occurrence, independently oxo or R d ;
• R h is, at each occurrence, independently selected from Ci-6 alkyl substituted with 0 to 2 R n , Ci-4 haloalkyl, and -(Co-3 alkylene)-R p ;
• R J and R m are, at each occurrence, independently H or Ci-4 alkyl
• R k is, at each occurrence, independently selected from H, Ci-4 alkyl, and
• R n is, at each occurrence, independently selected from: halo, OH, Ci-6 alkyl,
• Ci-4 haloalkyl Ci-4 alkoxy, Ci-4 haloalkoxy, cyano, -C(0)0H, -C(0)0(Ci-4 alkyl),
• R p is, at each occurrence, independently selected from: C3-6 cycloalkyl substituted with from 0 to 4 C1-4 alkyl; heterocyclyl including from 3-10 ring atoms, wherein from 1 to 3 ring atoms are each independently selected fromNH, N(CI-4 alkyl), O, and S, wherein the heterocyclyl is substituted with 0 to 4 independently selected C1-4 alkyl; phenyl substituted with 0 to 3 R n ; and heteroaryl including from 5 to 10 ring atoms, wherein from 1 to 4 ring atoms are each independently selected from N, NH,
• R la is independently Ci-6 alkyl substituted with 0 to 6 F, or C3-6 cycloalkyl substituted with 0 to 6 F.
• R 3 is independently halo or -(C0-3 alkylene)-(5-membered heteroaryl) wherein the heteroaryl includes 1 to 4 ring carbon atoms and 1 to 4 ring heteroatoms are each independently selected from: N, N(R f ), and S, and is substituted with from 0 to 3 R g .
• R 6 is independently: OH, OR a , -C(0)R a , -C(0)OR a , -NR b R c , -C(0)NR b R k , or heteroaryl including from 5 to 6 ring atoms, wherein from 1 -4 ring atoms are each independently selected from N, N(R f ), O, and S, wherein the heteroaryl is substituted with from 0 to 3 R d .
• R h is independently selected from Ci-6 alkyl, C1-4 haloalkyl, and -(C0-3 alkylene)-R p .
• the present invention provides a compound of Formula (I): or a stereoisomer, a tautomer or a pharmaceutically acceptable salt thereof, wherein:
• R 1 is, at each occurrence, independently:
• 1 to 4 ring atoms are each independently selected fromN, N(R f ), O, and S, wherein the heteroaryl is substituted with 0 to 3 R d ;
• R 2 is, at each occurrence, independently:
• Y is independently Ci-8 alkylene substituted with from 0 to 4 R e ;
• R 6 is, at each occurrence, independently: OH, OR a , -C(0)R a , -C(0)0R a , -NR b R c , -C(0)NR b R k , or heteroaryl including from 5 to 6 ring atoms, wherein from 1-4 ring atoms are each independently selected from N, N(R f ), O, and S, wherein the heteroaryl is substituted with from 0 to 3 R d ; (iv) -(Y 1 )n-Y 2 -(Y 3 )p-R 7 , wherein:
• each of Y 1 and Y 3 is, independently, Ci-3 alkylene substituted with from 0 to 2
• Y 2 is independently C3-6 cycloalkylene substituted with from 0 to 4 R g , or heterocycloalky lene including from 3-8 ring atoms, wherein from 1-2 ring atoms are each independently selected from N, N(R f ) and O, and wherein the heterocycloalkylene is substituted with from 0 to 4 R g , and
• R 7 is H, OH, -C(0)0R a , -NR b R c , -C(0)NR b R k , or heteroaryl including from 5- 6 ring atoms, wherein from 1-4 ring atoms are each independently selected from N, N(R f ), O, and S, and wherein the heteroaryl is substituted with from 0 to 4 R g ;
• Z 1 is Ci-3 alkylene substituted with from 0 to 6 F;
• Z 2 is -Ni ⁇ -, -0-, or -S-;
• Z 3 is C2-5 alkylene substituted with from 0 to 6 F;
• R 8 is OH, OR a , -C(0)R a , -C(0)OR a ; -NR b R c , -C(0)NR b R k , or heteroaryl including from 5-6 ring atoms, wherein from 1-4 ring atoms are each independently selected from N, N(R f ), O, and S, wherein the heteroaryl is substituted with from 0 to 3 R d ;
• R 3 is independently halo or -(C0-3 alkylene)-(5-membered heteroaryl) wherein the heteroaryl includes 1 to 4 ring carbon atoms and 1 to 4 ring heteroatoms are each independently selected from: N, N(R f ), O, and S, and is substituted with from 0 to 3 R g ; provided that when R 3 is furanyl, R 2 is other than C1-4 alkyl;
• R 4 is independently selected from: H, halo, cyano, OH, C1-4 alkoxy,
• R a is, at each occurrence, independently: (i) Ci-6 alkyl substituted with from 0 to 2 R e ;
• (v) -(Co-3 alkylene)-heteroaryl including from 5 to 10 ring atoms, wherein from 1 to 4 ring atoms are each independently selected from N, N(R f ), O, and S, wherein the heteroaryl is substituted with from 0 to 3 R d ;
• R b is, at each occurrence, independently H or R a ;
• R c is, at each occurrence, independently selected from: H, -C(0)R a , -C(0)OR a , -C(0)NR ) R k , -S(0)i-2R h , Ci-6 alkyl substituted with from 0 to 2 R e ,
• R b and R c together with the nitrogen atom to which each is attached form heterocyclyl including from 3 to 10 ring atoms, wherein from 1 to 3 ring atoms are each independently selected fromN(R f ), O, and S, and wherein the heterocyclyl is substituted with from 0 to 4 R g ;
• R d is, at each occurrence, independently selected from: halo, OH, cyano,
• R e is, at each occurrence, independently selected from: halo, OH, cyano,
• R f is, at each occurrence, independently selected from: H, OH, C1-4 alkyl,
• R g is, at each occurrence, independently oxo or R d ;
• R h is, at each occurrence, independently selected from Ci-6 alkyl, Ci-4 haloalkyl, and -(Co-3 alkylene)-R p ;
• R J and R m are, at each occurrence, independently H or Ci-4 alkyl
• R k is, at each occurrence, independently selected from H, Ci-4 alkyl, and
• R n is, at each occurrence, independently selected from: halo, OH, Ci-6 alkyl,
• R p is, at each occurrence, independently selected from: C3-6 cycloalkyl substituted with from 0 to 4 C1-4 alkyl; heterocyclyl including from 3-10 ring atoms, wherein from 1 to 3 ring atoms are each independently selected fromNH, N(CI-4 alkyl), O, and S, wherein the heterocyclyl is substituted with 0 to 4 independently selected C1-4 alkyl; phenyl substituted with 0 to 3 R n ; and heteroaryl including from 5 to 10 ring atoms, wherein from 1 to 4 ring atoms are each independently selected from N, NH,
• the present invention provides a compound of Formula (I), or a stereoisomer, a tautomer or a pharmaceutically acceptable salt thereof, within the scope of the first aspect, wherein:
• R 3 is independently -(C0-3 alkylene)-(5-membered heteroaryl) wherein the heteroaryl includes 2 to 4 ring carbon atoms and 1 to 3 ring heteroatoms are each independently selected from: N, N(R f ), and S, and is substituted with 0 to 3 R g ; and
• R 6 is, at each occurrence, independently selected from: OH, OR a , -C(0)R a , -C(0)OR a , -NR b R c , -C(0)NR b R k , -S02(Ci-4 alkyl), and heteroaryl including from 5 to 6 ring atoms, wherein from 1 to 4 ring atoms are each independently selected from N, N(R f ), O, and S, wherein the heteroaryl is substituted with from 0 to 3 R d .
• the present invention provides a compound of Formula (I), or a stereoisomer, a tautomer or a pharmaceutically acceptable salt thereof, within the scope of the first aspect, wherein: R 3 is independently -(Co-3 alkylene)-(5-membered heteroaryl) wherein the heteroaryl includes 2 to 4 ring carbon atoms and 1 to 3 ring heteroatoms are each independently selected from: N, N(R f ). and S, and is substituted with 0 to 3 R g ; and
• R 6 is, at each occurrence, independently: OH, OR a , -C(0)R a , -C(0)0R a ,
• heteroaryl including from 5 to 6 ring atoms, wherein from 1 to 4 ring atoms are each independently selected from N, N(R f ), O, and S, wherein the heteroaryl is substituted with from 0 to 3 R d .
• the invention provides a compound of Formula (Ila), (lib), (lie), (lid), (He), (Ilf), (Ilg), (Ilh) or (Hi):
• the invention provides a compound of Formula (Ila), (lib), (lie), (lid), (He), (Ilf), (Ilg-l), or (Ilh):
• the invention provides a compound of Formula (Ila), (lib), (lie), (lid) or (He):
• the invention provides a compound of Formula (Ila), (lib), (lie), (lid), (He), (Ilf), (Ilg), (Ilh) or (Hi) or a stereoisomer, a tautomer or a pharmaceutically acceptable salt thereof, wherein:
• R 1 is, at each occurrence, independently selected from H, halo and Ci -4 alkyl;
• R 2 is, at each occurrence, independently selected from: H, Ci -4 alkyl substituted
• Y is independently Ci-6 alkylene substituted with from 0 to 3 R e ;
• R 3 is, at each occurrence, independently -(Co- 2 alkylene)-(5-membered heteroaryl) wherein the heteroaryl includes 2 to 4 ring carbon atoms and 1 to 3 ring heteroatoms are each independently selected from: N, N(R f ), and S, wherein the heteroaryl is substituted with from 0 to 2 R g ; provided that when R 3 is furanyl, R 2 is other than Ci-4 alkyl;
• R 4 is, at each occurrence, independently selected from H, halo and Ci-4 alkyl;
• R 6 is independently selected from: OH, CN, OR a , -C(0)R a , NR b R c , -C(0)NR b R k ,
• -Y 2 -R 7 is independently selected from C3-6 cycloalkyl substituted with 0 to 2 R d ,
• R a is, at each occurrence, independently:
• (iii) -(C0-2 alkylene)-heterocyclyl including from 4 to 10 ring atoms, wherein from 1 to 3 ring atoms are each independently selected from N(R f ), O, and S, wherein the heterocyclyl is substituted with from 0 to 3 R g ;
• (v) -(C0-2 alkylene)-heteroaryl including from 5 to 10 ring atoms, wherein from 1 to 3 ring atoms are each independently selected from N, N(R f ), O, and S, wherein the heteroaryl is substituted with from 0 to 3 R d ;
• R b is, at each occurrence, independently H or R a ;
• R c is, at each occurrence, independently selected from: H, -C(0)R a , -C(0)0R a , -C(0)NR ) R k , -S(0)2R h , Ci-6 alkyl substituted with from 0 to 2 R e ,
• R b and R c together with the nitrogen atom to which each is attached form heterocyclyl including from 3 to 10 ring atoms, wherein from 1 to 3 ring atoms are each independently selected fromN(R f ), O, and S, and wherein the heterocyclyl is substituted with from 0 to 3 R g ;
• R d is, at each occurrence, independently selected from: OH, halo, CN, C1-4 alkoxy, Ci-4 haloalkyl, C1-4 haloalkoxy, -C(0)0(Ci-4 alkyl), NH2, N(CI-4 alkyl)2, -CONH2, -CONH(CI-4 alkyl), -NHC(0)(Ci- 4 alkyl), -NHC(0)0(Ci- 4 alkyl), -S(0) 2 (Ci- 4 alkyl), benzoxy, C1-4 alkyl substituted with from 0 to 2 R e , phenyl, and heteroaryl including from 5 to 6 ring atoms, wherein from 1 to 4 ring atoms are each independently selected from N, N(R f ). O, and S, wherein the heteroaryl is substituted with 0 to 2 R n ;
• R e is, at each occurrence, independently selected from: halo, OH, CN, Ci-4 alkoxy, Ci-4 haloalkyl, Ci-4 haloalkoxy, -CONH2, and -CONH(CI-4 alkyl);
• R f is, at each occurrence, independently selected from H, C1-4 alkyl
• R g is, at each occurrence, independently oxo or R d ;
• R h is independently C 1-4 alkyl substituted with 0 to 2 R n , C3-6 cycloalkyl, or phenyl;
• R j is independently H or C1-4 alkyl
• R k is independently selected from H, C1-4 alkyl and phenyl
• R n is, at each occurrence, independently selected from: halo, C 1-4 alkyl, and Ci -4 alkoxy.
• R b is independently selected from H, C 1-4 alkyl, and
• R e is independently selected from: halo, OH, C1-4 alkoxy,
• Ci-4 haloalkyl, and C1-4 haloalkoxy are examples of substituents for the following haloalkyl, and C1-4 haloalkoxy.
• R f is independently selected from H, C 1-4 alkyl
• R g is independently OH or C1-4 alkoxy.
• R h is independently C1-4 alkyl or phenyl.
• the invention provides a compound of Formula (Ila), (lib), (lie), (lid), or (He), or a stereoisomer, a tautomer or a pharmaceutically acceptable salt thereof, wherein:
• R 1 is, at each occurrence, independently selected from H, halo and C 1-4 alkyl
• R 2 is, at each occurrence, independently selected from: H, -(CH2)I-3-R 6 , -(CH 2 )i-30(CH 2 )2-30R a , and -(CH 2 )I-2-Y 2 -R 7 ;
• R 3 is independently -(C0-2 alkylene)-(5-membered heteroaryl) wherein the heteroaryl includes 2 to 4 ring carbon atoms and 1 to 3 ring heteroatoms are each independently selected from: N, N(R f ), and S, wherein the heteroaryl is substituted with from 0 to 2 R g ;
• R 4 is, at each occurrence, independently selected from H, halo and C 1-4 alkyl
• R 6 is, at each occurrence, independently selected from: OH, OR a , -NR b R c , -C(0)NR b R k , or heteroaryl including from 5 to 6 ring atoms, wherein from 1 to 4 ring atoms are each independently selected from N, N(R f ), O, and S, wherein the heteroaryl is substituted with from 0 to 3 R d ;
• R a is, at each occurrence, independently:
• (iii) -(C0-2 alkylene)-heterocyclyl including from 4 to 10 ring atoms, wherein from 1 to 3 ring atoms are each independently selected from N(R f ), O, and S, wherein the heterocyclyl is substituted with from 0 to 3 R g ;
• (v) -(C0-2 alkylene)-heteroaryl including from 5 to 10 ring atoms, wherein from 1 to 3 ring atoms are each independently selected from N, N(R f ), O, and S, wherein the heteroaryl is substituted with from 0 to 3 R d ;
• R b is, at each occurrence, independently selected from H, C1-4 alkyl, and
• R c is, at each occurrence, independently selected from: H, -C(0)R a , -C(0)0R a , -C(0)NR ) R k , -S(0)2R h , Ci-6 alkyl substituted with from 0 to 2 R e ,
• R d is, at each occurrence, independently selected from: halo, CN, Ci-4 alkoxy,
• Ci-4 alkyl substituted with from 0 to 2 R e and heteroaryl including from 5 to 6 ring atoms, wherein from 1 to 4 ring atoms are each independently selected from N, N(R f ), O, and S, wherein the heteroaryl is substituted with 0 to 2 R n ;
• R e is, at each occurrence, independently selected from: F, Cl, OH, CM alkoxy,
• R f is, at each occurrence, independently H or CM alkyl
• R h is independently CM alkyl or phenyl
• R 1 is independently H or CM alkyl
• R k is independently selected from H, CM alkyl and phenyl
• R n is, at each occurrence, independently selected from: F, Cl, C alkyl, and Ci -4 alkoxy.
• the invention provides a compound of Formula (Ila):
• R 1 is independently selected from H, F and CM alkyl
• R 2 is independently selected from: H, CM alkyl substituted with 0 to 3 F, -(CH 2 )I-3-R 6 , -(CH 2 )I -2 CH(CH 3 )OH, -(CH 2 )I -2 C(CH 3 ) 2 OH, -(CH 2 )I -2 CH(OCH 3 )CH 2 OH, alkyl), -(CH 2 )i-30(CH 2 )2-30R a , -CH 2 CH(CH 3 )NHC(0)R a , and -(CH 2 )I -2 -Y 2 -R 7 ;
• R 3 is independently 5-membered heteroaryl wherein the heteroaryl includes 3 to 4 ring carbon atoms and 1 to 2 ring heteroatoms are each independently selected from: N, NH, and S; provided that when R 3 is furanyl, R 2 is other than Ci-4 alkyl;
• R 4 is independently selected from H, halo and Ci-4 alkyl
• R 6 is independently selected from: OH, OR a , NR b R c , -NR b C(0)R a , -C(0)NR b R k ,
• heteroaryl including from 5 to 6 ring atoms, wherein from 1 to 4 ring atoms are each independently selected from N, N(R f ), O, and S, wherein the heteroaryl is substituted with from 0 to 3 R d ;
• -Y 2 -R 7 is independently selected from C3-6 cycloalkyl substituted with 0 to 2 R d ,
• R a is, at each occurrence, independently selected from: C1-4 alkyl substituted with
• R e 0 to 2 R e , C3-6 cycloalkyl, , phenyl, benzyl, oxazolyl, isoxazolyl, thiazolyl,
• R b is, at each occurrence, independently H, C1-4 alkyl, or phenyl substituted with 0 to 2 F;
• R c is independently C1-4 alkyl, -(C0-3 alkylene)-(phenyl substituted with from 0 to 3 R n ), or -(C0-3 alkylene)-heteroaryl including from 5-6 ring atoms, wherein from 1-4 ring atoms are each independently selected from N, N(R f ), O, and S, wherein the heteroaryl is substituted with from 0 to 3 R n ;
• R d is, at each occurrence, independently selected from: halo, CN,-CH 2 OH,
• R e is, at each occurrence, independently selected from: halo, OH, Ci-4 alkoxy,
• R f is, at each occurrence, independently H or Ci-4 alkyl
• R h is independently Ci-4 alkyl or phenyl
• R 1 is independently H or Ci-4 alkyl
• R k is independently selected from H, Ci-4 alkyl and phenyl
• R n is, at each occurrence, independently selected from: halo, Ci-4 alkyl, and Ci -4 alkoxy.
• the invention provides a compound of Formula (Ila), or a stereoisomer, a tautomer or a pharmaceutically acceptable salt thereof, wherein:
• R 1 is independently selected from H, F and Ci-4 alkyl
• R 2 is independently selected from: H, Ci-4 alkyl substituted with 0 to 3 F, -(CH 2 )I-3-R 6 , -(CH 2 ) I -30(CH 2 ) 2 -3 OR a , and -(CH 2 )I -2 -Y 2 -R 7 ;
• R 3 is independently 5-membered heteroaryl wherein the heteroaryl includes 3 to 4 ring carbon atoms and 1 to 2 ring heteroatoms are each independently selected from: N, NH, and S;
• R 4 is independently selected from H, halo and Ci-4 alkyl
• R 6 is independently selected from: OH, OR a , NR b R c , -NR b C(0)R a ,
• ring atoms from 5 to 6 ring atoms, wherein from 1 to 4 ring atoms are each independently selected fromN, N(R f ). O, and S, wherein the heteroaryl is substituted with from 0 to 3 R d ;
• R a is, at each occurrence, independently selected from: Ci-4 alkyl substituted with
• R e 0 to 1 R e , C3-6 cycloalkyl, , phenyl, benzyl, oxazolyl, isoxazolyl, thiazolyl,
• R b is, at each occurrence, independently H or C1-4 alkyl
• R c is independently C1-4 alkyl, -(C0-3 alkylene)-(phenyl substituted with from 0 to 3 R n ), or -(C0-3 alkylene)-heteroaryl including from 5-6 ring atoms, wherein from 1-4 ring atoms are each independently selected from N, N(R f ), O, and S, wherein the heteroaryl is substituted with from 0 to 3 R n ;
• R d is, at each occurrence, independently selected from: halo, CN,-CH20H,
• Ci-4 alkyl C1-4 alkoxy, C1-4 haloalkyl, C1-4 haloalkoxy, -C(0)0(Ci-4 alkyl),
• R e is, at each occurrence, independently selected from: halo, OH, C 1-4 alkoxy,
• R f is, at each occurrence, independently H or C1-4 alkyl
• R h is independently C1-4 alkyl or phenyl
• R 1 is independently H or C1-4 alkyl
• R k is independently selected from H, C1-4 alkyl and phenyl
• R n is, at each occurrence, independently selected from: halo, C1-4 alkyl, and
• the invention provides a compound of Formula (Ila), or a stereoisomer, a tautomer or a pharmaceutically acceptable salt thereof, wherein:
• R 1 is independently selected from H, F and C1-4 alkyl
• R 2 is independently selected from: -(CH2)I-3-R 6 , -(CH2)i-30(CH2)2-30R a , and -(CH 2 )I-2-Y 2 -R 7 ;
• R 3 is independently 5-membered heteroaryl wherein the heteroaryl includes 3 to 4 ring carbon atoms and 1 to 2 ring heteroatoms are each independently selected from: N, NH, O, and S;
• R 4 is independently selected from H, F and C1-4 alkyl
• R 6 is independently selected from: OH, OR a , NR b R c , -NR b C(0)R a , , and heteroaryl including from 5 to 6 ring atoms, wherein from 1 to 4 ring atoms are each independently selected from N, N(R f ), O, and S, wherein the heteroaryl is substituted with from 0 to 3 R d ;
• R a is, at each occurrence, independently selected from: C1-4 alkyl substituted with 0 to 1 OH, tetrahydro-2H-pyranyl, phenyl, benzyl, oxazolyl, isoxazolyl, thiazolyl, N-(CI-4 alkyl)-pyrazolyl, pyrazol-l-yl, N-(CI-4 alkyl)-imidazolyl, pyridyl, pyridazinyl, pyrimidyl, pyrazinyl, N-(CI-4 alkyl)-benzimidazolyl, pyrazolo[l,5-a]pyrimidinyl and wherein each ring moiety is substituted with 0 to 3 R d ;
• R b is, at each occurrence, independently H or C1-4 alkyl
• R c is independently C1-4 alkyl, -(C0-3 alkylene)-(phenyl substituted with from 0 to 3 R n ), or -(C0-3 alkylene)-heteroaryl including from 5-6 ring atoms, wherein from 1-4 ring atoms are each independently selected from N, N(R f ), O, and S, wherein the heteroaryl is substituted with from 0 to 3 R n ;
• R d is, at each occurrence, independently selected from: F, Cl, CN,-CH 2 OH,
• R f is, at each occurrence, independently H or Ci-4 alkyl
• R h is independently Ci-4 alkyl or phenyl
• R j is independently H or Ci-4 alkyl
• R k is independently selected from H, Ci-4 alkyl and phenyl
• R n is, at each occurrence, independently selected from: F, Cl, Ci-4 alkyl, and Ci -4 alkoxy.
• the invention provides a compound of Formula (Ila), or a stereoisomer, a tautomer, or a pharmaceutically acceptable salt thereof, wherein:
• R 1 is H
• R 2 is independently selected from: H, Ci-4 alkyl substituted with 0 to 3 F, -(CH 2 )I-3-R 6 , -(CH 2 )I -2 CH(CH 3 )OH, -(CH 2 )I -2 C(CH 3 ) 2 OH, -(CH 2 )I -2 CH(OCH 3 )CH 2 OH, -CH(CH 3 )(CH 2 )I -2 OH, -(CH 2 )I -2 CH(OH)CH 2 F, -(CH 2 )I -2 CH(CH 3 )0(CI-4 alkyl), -(CH 2 )i -3 0(CH 2 ) 2-3 0R a , -CH 2 CH(CH 3 )NHC(0)R a , and -(CH 2 )I -2 -Y 2 -R 7 ;
• R 3 is independently selected from
• R 4 is independently H, F, or Cl
• R 6 is independently selected from: OH, OR a , NR b R c , -NR b C(0)R a , -C(0)NR b R k , -NHC(0)0(CI-6 alkyl), -NHC(0)0Ph, -NHC(0)N(CI-4 alkyl) 2 , -NHC(0)N(CI-4 alkyl)Ph,
• -NHS(0) 2 (CI-4 alkyl), -S0 2 (Ci- 4 alkyl), v 3 ⁇ 4 X> and heteroaryl including from 5 to 6 ring atoms, wherein from 1 to 4 ring atoms are each independently selected from N, N(R f ), O, and S, wherein the heteroaryl is substituted with from 0 to 3 R d ;
• -Y 2 -R 7 is independently selected from: C3-6 cycloalkyl substituted with 0 to 2 R d ,
• R a is, at each occurrence, independently selected from: C1-4 alkyl substituted with
• R e 0 to 2 R e , C3-6 cycloalkyl, , phenyl, benzyl, oxazolyl, isoxazolyl, thiazolyl,
• R b is, at each occurrence, independently H, C1-4 alkyl, or phenyl substituted with 0 to 2 F;
• R c is independently C1-4 alkyl, -(C0-3 alkylene)-(phenyl substituted with from 0 to 3 R n ), or -(C0-3 alkylene)-heteroaryl including from 5-6 ring atoms, wherein from 1-4 ring atoms are each independently selected from N, N(R f ), O, and S, wherein the heteroaryl is substituted with from 0 to 3 R n ;
• R d is, at each occurrence, independently selected from: F, Cl, CN,-CH20H,
• R e is, at each occurrence, independently selected from: F, Cl, OH, C 1-4 alkoxy,
• R f is, at each occurrence, independently H or C1-4 alkyl
• R k is independently selected from H, C1-4 alkyl and phenyl
• R n is, at each occurrence, independently selected from: F, Cl, C 1-4 alkyl, and Ci -4 alkoxy.
• the invention provides a compound of Formula (Ila), or a stereoisomer, a tautomer, or a
• R 1 is H
• R 2 is independently selected from: H, Ci-4 alkyl substituted with 0 to 3 F, -(CH 2 )I-3-R 6 , -(CH 2 ) l -30(CH 2 ) 2-3 OR a , and -(CH 2 )i -2 -Y 2 -R 7 ;
• R is independently selected from
• R 4 is independently H, F, or Cl
• R 6 is independently selected from: OH, OR a , NR b R c , -NR b C(0)R a
• heteroaryl including from 5 to 6 ring atoms, wherein from 1 to 4 ring atoms are each independently selected from N, N(R f ), O, and S, wherein the heteroaryl is substituted with from 0 to 3 R d ; i_L K °
• -Y 2 -R 7 is independently selected from: - ⁇ , .
• R a is, at each occurrence, independently selected from: Ci-4 alkyl substituted with
• R e 0 to 1 R e , C3-6 cycloalkyl, 'rif,,, phenyl, benzyl, oxazolyl, isoxazolyl, thiazolyl, N-(CI-4 alkyl)-pyrazolyl, pyrazol-l-yl, N-(CI-4 alkyl)-imidazolyl, pyridyl, pyridazinyl, pyrimidyl, pyrazinyl, N-(CI-4 alkyl)-benzimidazolyl, pyrazolo[l,5-a]pyrimidinyl and wherein each ring moiety is substituted with 0 to 3 R d ;
• R b is, at each occurrence, independently H or Ci- 4 alkyl
• R c is independently Ci-4 alkyl, -(Co-3 alkylene)-(phenyl substituted with from 0 to 3 R n ), or -(Co-3 alkylene)-heteroaryl including from 5-6 ring atoms, wherein from 1-4 ring atoms are each independently selected from N, N(R f ), O, and S, wherein the heteroaryl is substituted with from 0 to 3 R n ;
• R d is, at each occurrence, independently selected from: F, Cl, CN,-CH20H,
• R e is, at each occurrence, independently selected from: F, Cl, OH, Ci-4 alkoxy,
• R f is, at each occurrence, independently H or Ci-4 alkyl
• R k is independently selected from H, Ci-4 alkyl and phenyl
• R n is, at each occurrence, independently selected from: F, Cl, Ci-4 alkyl, and
• the invention provides a compound of Formula (Ila), or a stereoisomer, a tautomer, or a
• R 1 is H
• R 2 is independently selected from -(CH2)I-3-R 6 , -(CH2)i-30(CH2)2-30R a , and -(CH 2 )I-2-Y 2 -R 7 ;
• R 3 is independently selected from
• R 4 is H
• R 6 is independently selected from: OH, OR a , NR b R c , -NR b C(0)R a -C(0)NH(CI-4 alkyl), -C(0)NHPh, -NHC(0)0(Ci-e alkyl), -NHC(0)N(CI-4 alkyl) 2 ,
• heteroaryl including from 5 to 6 ring atoms, wherein from 1 to 4 ring atoms are each independently selected from N, N(R f ), O, and S, wherein the heteroaryl is substituted with from 0 to 3 R d ;
• -Y -R 7 is independently selected from:
• R a is, at each occurrence, independently selected from: Ci-4 alkyl substituted with 0 to 1 OH, tetrahydro-2H-pyranyl, phenyl, benzyl, oxazolyl, isoxazolyl, thiazolyl, N-(CI-4 alkyl)-pyrazolyl, pyrazol-l-yl, N-(CI-4 alkyl)-imidazolyl, pyridyl, pyridazinyl, pyrimidyl, pyrazinyl, N-(CI-4 alkyl)-benzimidazolyl, pyrazolo[l,5-a]pyrimidinyl and wherein each ring moiety is substituted with 0 to 3 R d ;
• R b is, at each occurrence, independently H or Ci-4 alkyl
• R c is independently Ci-4 alkyl, -(Co-3 alkylene)-(phenyl substituted with from 0 to 3 R n ), or -(Co-3 alkylene)-heteroaryl including from 5-6 ring atoms, wherein from 1-4 ring atoms are each independently selected from N, N(R f ), O, and S, wherein the heteroaryl is substituted with from 0 to 3 R n ;
• R d is, at each occurrence, independently selected from: F, Cl, CN,-CH 2 OH,
• R f is, at each occurrence, independently H or Ci-4 alkyl
• R n is, at each occurrence, independently selected from: F, Cl, Ci-4 alkyl, and
• the invention provides a compound of Formula (Ila), or a tautomer, or a pharmaceutically acceptable salt thereof, wherein:
• R 1 is H
• R 2 is independently selected from: H, C1-4 alkyl substituted with 0 to 3 F, -(CH 2 )I-3-R 6 , -(CH 2 )I- 2 CH(CH3)OH, -(CH 2 )I-2C(CH3) 2 OH, -(CH 2 )I-2CH(OCH3)CH 2 OH, -CH(CH3)(CH 2 )I- 2 OH, -(CH 2 )I-2CH(OH)CH 2 F, -(CH 2 )I- 2 CH(CH3)0(CI-4 alkyl), -CH 2 CH(CH 3 )NHC(0)R a , and -(CH 2 )I-2-Y 2 -R 7 ;
• R 3 is independently
• R 4 is independently H, F, or Cl
• R 6 is independently selected from: OH, OR a , N(CI-4 alkyl)2, -NH(CI-4 alkyl), -NH(CH2)i-2(phenyl substituted with 0 to 1 R d ), -N(CI-2 alkyl)Bn, -NH(pyridyl), -NR b C(0)R a , -NHC(0)0(Ci-e alkyl), -NHC(0)0Ph, -NHC(0)N(Ci- 4 alkyl) 2 ,
• heteroaryl selected from imidazolyl, pyrazolyl, oxazolyl, isoxazolyl, thiazolyl, oxadiazolyl and pyridyl, wherein the heteroaryl is substituted with 0 to 2 R d ;
• -Y 2 -R 7 is independently selected from: C3-6 cycloalkyl substituted with 0 to 2 R d ,
• R a is, at each occurrence, independently selected from: C1-4 alkyl substituted with
• R e 0 to 2 R e , C3-6 cycloalkyl, , phenyl, oxazolyl, isoxazolyl, thiazolyl,
• R b is independently H or Ci- 2 alkyl
• R d is, at each occurrence, independently selected from: F, Cl, CN, -CH 2 OH, Ci-4 alkyl, C1-4 alkoxy, C1-4 haloalkyl, C1-4 haloalkoxy, -CONH 2 , NH 2 , N(CI-4 alkyl) 2 , -C(0)0(Ci-4 alkyl), benzoxy, phenyl, and pyridyl; and
• R e is independently selected from F, OH and C1-4 alkoxy.
• the invention provides a compound of Formula (Ila), or a tautomer, or a pharmaceutically acceptable salt thereof, wherein:
• R 1 is H
• R 2 is independently selected from: H, C1-4 alkyl substituted with 0 to 3 F, or -(CH 2 ) 2 -3-R 6 ;
• R 3 is independently
• R 4 is independently H, F, or Cl
• R 6 is independently selected from: OH, OR a , N(CI-4 alkyl)2, -NR b C(0)R a , -NHC(0)0(CI-6 alkyl), -NHC(0)N(CI-4 alkyl) 2 , -NHC(0)CH 2 0CH 2 CF 3 ,
• heteroaryl selected from imidazolyl, pyrazolyl, oxazolyl, isoxazolyl, thiazolyl, oxadiazolyl and pyridyl, wherein heteroaryl is substituted with 0 to 2 R d ;
• R a is, at each occurrence, independently selected from: Ci-4 alkyl, C3-6 cycloalkyl, , phenyl, oxazolyl, isoxazolyl, thiazolyl,
• R b is independently H or C1-2 alkyl
• R d is, at each occurrence, independently selected from: F, Cl, CN, -CH2OH, Ci-4 alkyl, C1-4 alkoxy, C1-4 haloalkyl, C1-4 haloalkoxy, benzoxy, phenyl, and pyridyl.
• the invention provides a compound of Formula (Ila), or a tautomer, or a pharmaceutically acceptable salt thereof, wherein:
• R 1 is H
• R 2 is -(CH 2 ) 2 -3-R 6 ;
• R 3 is independently
• R 4 is H
• R 6 is independently selected from: OH, OR a , N(CI-4 alky 1)2, -NR b C(0)R a , -C(0)NHPh, -NHC(0)0(Ci-e alkyl), -NHC(0)N(Ci- 4 alkyl) 2 , -NHS(0) 2 (CI-4 alkyl), pyrazol-l-yl substituted with 0 to 2 R d ;
• R a is, at each occurrence, independently selected from: C1-4 alkyl
• R b is independently H or C1-2 alkyl
• R d is, at each occurrence, independently selected from: F, Cl, CN, -CH2OH,
• the invention provides a compound of Formula (Illa-l):
• R 2 is independently selected from: H, Ci-4 alkyl substituted with 0 to 3 F, -(CH 2 )I- 2 OCHF 2 , -(CH 2 ) 2 0(CI-4 alkyl), -(CH 2 ) 2 0(CH 2 ) 2 (Ci- 4 alkoxy),
• heteroaryl is selected from imidazolyl, pyrazolyl, oxazolyl, isoxazolyl, thiazolyl, oxadiazolyl and pyridyl, and the heteroaryl is substituted with 0 to 2 R d ;
• R 3 is independently
• R a is independently selected from: C 3 -6 cycloalkyl, , phenyl, oxazolyl, thiazolyl, N-(CI-4 alkyl)-pyrazolyl, N-(CI-4 alkyl)-imidazolyl, pyridyl, pyrimidyl, pyrazinyl, and N-(CI-4 alkyl)-benzimidazolyl; wherein each ring moiety is substituted with 0 to 2 R d ;
• R d is, at each occurrence, independently selected from: F, Cl, CN, Ci-4 alkyl, Ci-4 alkoxy, Ci-4 haloalkyl, Ci-4 haloalkoxy, NH 2 , -C(0)0(Ci-4 alkyl), phenyl, and benzoxy; and
• R e is independently selected from F, OH and Ci-4 alkoxy.
• the invention provides a compound of Formula (Illa-l):
• R 2 is independently selected from: H, Ci-4 alkyl substituted with 0 to 3 F, -(CH 2 ) 2 0(CI-4 alkyl), -(CH 2 ) 2-3 NHC(0)R a , -(CH 2 ) 2-3 NHC(0)CH 2 0CH 2 CF 3 ,
• heteroaryl is selected from imidazolyl, pyrazolyl, oxazolyl, isoxazolyl, thiazolyl, oxadiazolyl and pyridyl, and heteroaryl is substituted with 0 to 2 R d ;
• R a is independently selected from: C3-6 cycloalkyl, . phenyl, oxazolyl, thiazolyl, N-(CI-4 alkyl)-pyrazolyl, N-(CI-4 alkyl)-imidazolyl, pyridyl, pyrimidyl, pyrazinyl, and N-(CI-4 alkyl)-benzimidazolyl; wherein each ring moiety is substituted with 0 to 2 R d ; and
• R d is, at each occurrence, independently selected from: F, Cl, CN, C1-4 alkyl, Ci-4 alkoxy, C1-4 haloalkyl, and phenyl.
• the invention provides a compound of Formula (Illa-l):
• R 2 is independently selected from: H, C1-4 alkyl substituted with 0 to 3 F, -(CH 2 ) 2 0(CI-4 alkyl), -(CH 2 ) 2-3 NHC(0)R a , -(CH 2 ) 2-3 NHC(0)CH 2 0CH 2 CF 3 ,
• heteroaryl is selected from imidazolyl, pyrazolyl, oxazolyl, isoxazolyl, thiazolyl, oxadiazolyl and pyridyl, and heteroaryl is substituted with 0 to 2 R d ;
• R 3 is independently
• R a is independently selected from: C 3 -6 cycloalkyl, phenyl, oxazolyl, thiazolyl, N-(CI-4 alkyl)-pyrazolyl, N-(CI-4 alkyl)-imidazolyl, pyridyl, pyrimidyl, pyrazinyl, and N-(CI- 4 alkyl)-benzimidazolyl; wherein each ring moiety is substituted with 0 to 2 R d ; and
• R d is, at each occurrence, independently selected from: F, Cl, CN, C1-4 alkyl,
• Ci-4 alkoxy, C1-4 haloalkyl, and phenyl in another aspect, provides a compound of Formula (Ilia):
• R 2 is independently selected from -(CH2)2--NHC(0)R a and
• R a is independently selected from: phenyl, oxazolyl, thiazolyl,
• Ci-4 alkoxy and Ci- 4 haloalkyl are examples of compounds that are identical to each other.
• the invention provides a compound of Formula (Ilia): or a tautomer or a pharmaceutically acceptable salt thereof, wherein:
• R 2 is independently Ci-4 alkyl substituted with 0 to 3 F, -(CH2)2-40(CI-4 alkyl), -(CH 2 )2- 3 NHC(0)R a , -(CH 2 )2-3NHC(0)0(CI- 4 alkyl), -(CH 2 ) 2 C(0)NH2,
• heteroaryl is selected from imidazolyl, pyrazolyl, oxazolyl, isoxazolyl, thiazolyl, oxadiazolyl and pyridyl, and heteroaryl is substituted with 0 to 2 R d ;
• R a is independently selected from: oxazolyl, isoxazolyl, thiazolyl,
• R d is, at each occurrence, independently selected from F, Cl, Ci -4 alkyl, Ci-4 alkoxy and phenyl.
• the invention provides a compound of Formula (Ilia): or a tautomer or a pharmaceutically acceptable salt thereof, wherein:
• R 2 is -(CH 2 )2-NHC(0)R a ;
• R a is independently selected from: oxazolyl, thiazolyl, N-methyl-imidazolyl, pyridyl and pyrazinyl; wherein each ring moiety is substituted with 0 to 2 R d ; and
• R d is, at each occurrence, independently selected from F, Cl and Ci-4 alkyl.
• the invention provides a compound of Formula (Ilia): or a tautomer or a pharmaceutically acceptable salt thereof, wherein:
• R d is, at each occurrence, independently selected from F, Cl, CFb, and OCFb.
• the invention provides a compound of Formula (Ilia): or a tautomer or a pharmaceutically acceptable salt thereof, wherein:
• R d is, at each occurrence, independently selected from F, Cl and CFb.
• the invention provides a compound of Formula (Illb-l):
• R 2 is independently selected from H, Ci-4 alkyl substituted with 0 to 3 F,
• R a is independently Ci-4 alkyl substituted with 0 to 1 R e , C3-6 cycloalkyl substituted with 0 to 2 R d , , phenyl or heteroaryl selected from oxazolyl, isoxazolyl, thiazolyl, pyridyl and pyrazinyl, wherein said phenyl and heteroaryl are substituted with 0 to 2 R d ;
• R d is, at each occurrence, independently selected from: F, Cl, OH, CN, C1-4 alkyl, Ci-4 alkoxy, C1-4 haloalkyl, NH2, N(CI- 4 alkyl)2, -NHC(0)(Ci- 4 alkyl), and phenyl;
• R e is independently selected from F, OH and C1-4 alkoxy
• R f is, at each occurrence, independently selected from: H, C1-4 alkyl,
• the invention provides a compound of Formula (Illb-l), or a stereoisomer, a tautomer or a pharmaceutically acceptable salt thereof, wherein:
• R 2 is independently selected from H, C1-4 alkyl substituted with 0 to 3 F,
• heteroaryl is selected from imidazolyl, pyrazolyl, oxazolyl, isoxazolyl, thiazolyl, oxadiazolyl, pyridyl and pyridazinyl, and the heteroaryl is substituted with 0 to 2 R d ;
• R a is independently Ci-4 alkyl substituted with 0 to 1 , phenyl or heteroaryl selected from oxazolyl, pyridyl and pyrazinyl, wherein said phenyl and heteroaryl are substituted with 0 to 2 R d ; and
• R d is, at each occurrence, independently selected from: F, Cl, CN, Ci-4 alkyl, Ci-4 alkoxy, and Ci-4 haloalkyl.
• the invention provides a compound of Formula (Illb-l), or a stereoisomer, a tautomer or a pharmaceutically acceptable salt thereof, wherein: R 3 is independently
• the invention provides a compound of Formula (IIIb-2),
• R 2 is independently selected from H, Ci-4 alkyl substituted with 0 to 3 F, -(CH 2 )2-40H, -(CH 2 ) 2 -4CN, -(CH 2 )I- 2 CH(CH 3 )OH, -(CH 2 )I- 2 C(CH 3 ) 2 OH,
• R e is independently selected from F, OH and Ci-4 alkoxy.
• the invention provides a compound of Formula (IIIb-2), or a stereoisomer, a tautomer or a pharmaceutically acceptable salt thereof, wherein:
• R 2 is independently selected from H, -CH2CHF2, -(CH2)2-40H, -(CH2)2-4CN, -CH 2 CH(CH 3 )OH, -CH 2 C(CH 3 ) 2 OH, -CH 2 CH(OH)CH 2 OH, -CH 2 CH(OH)CH 2 CH 3 , -CH(CH 3 )(CH 2 ) 2 OH, -CH 2 CH(CH 3 )CH 2 OH, -CH 2 CH(OCH 3 )CH 2 OH,
• the invention provides a compound of Formula (Illb):
• R 2 is independently selected from H, Ci-4 alkyl substituted with 0 to 3 F,
• heteroaryl is selected from imidazolyl, pyrazolyl, oxazolyl, isoxazolyl, thiazolyl, oxadiazolyl and pyridyl, and heteroaryl is substituted with 0 to 2 R d ;
• R 3 is independently
• R a is independently Ci-4 alkyl, C 3 -6 cycloalkyl, 1_2 , phenyl or heteroaryl selected from oxazolyl, isoxazolyl, thiazolyl, pyridyl and pyrazinyl, wherein said phenyl and heteroaryl are substituted with 0 to 2 R d ;
• R d is, at each occurrence, independently selected from: F, Cl, CN, Ci-4 alkyl,
• R f is, at each occurrence, independently selected from: H, Ci-4 alkyl, C(0)(Ci-4 alkyl), and C(0)(Ci- 4 haloalkyl).
• the invention provides a compound of Formula (Illb), or a tautomer or a pharmaceutically acceptable salt thereof, wherein:
• R 2 is independently selected from H, C1-4 alkyl, -(CH2)I-2CHF2,
• R a is independently C1-4 alkyl, , phenyl or heteroaryl selected from oxazolyl, pyridyl and pyrazinyl, wherein said phenyl and heteroaryl are substituted with 0 to 2 R d
• the invention provides a compound of Formula (Illb), or a tautomer or a pharmaceutically acceptable salt thereof, wherein:
• the invention provides a compound of Formula (Hit):
• R 2 is independently selected from -(CH2)2N(CI-4 alky 1)2, -(CH2)2--OR a ,
• R a is independently selected from: C 1-4 alkyl substituted with from 0 to 2 F, , and heteroaryl selected from thiazolyl and pyridyl, wherein said heteroaryl is substituted with 0 to 2 R d ;
• R d is, at each occurrence, independently selected from: F, Cl, CN, C1-4 alkyl, Ci-4 alkoxy and C1-4 haloalkyl.
• the invention provides a compound of Formula (Illg-l):
• R 1 is independently H, Cl or C1-4 alkyl
• R la is independently H or C 1-4 alkyl
• R 2 is independently selected from -(CH2)I-4-OH, -(CH2)i-2-OR a ,
• R a is independently selected from: Ci-4 alkyl substituted with from 0 to 2 F, i— o
• heteroaryl selected from thiazolyl, oxazolyl, N-CI-4 alkyl-imidazolyl, and pyridyl, wherein said heteroaryl is substituted with 0 to 2 R d ;
• R d is, at each occurrence, independently selected from: F, Cl, OH, CN, Ci-4 alkyl, Ci-4 alkoxy, Ci-4 haloalkyl, and -NHC(0)(CI-4 alkyl); and
• R e is independently selected from F, OH, Ci-4 alkoxy and Ci-4 haloalkyl.
• the invention provides a compound of Formula (Illg-l):
• R la is H
• R 2 is independently selected from -(CH2)I-4-OH,
• R 3 is independently
• the invention provides a compound of Formula (Illg):
• R 2 is independently selected from -(03 ⁇ 4)i-2NH2, -(CH2)I-2N(CI-4 alkyl)2, -(CH 2 )I- 2 NH(CI-4 alkyl substituted with 0 to 1 R e ), -(CH2)i-2--NHC(0)R a ;
• R a is independently selected from: C1-4 alkyl substituted with from 0 to 2 F, , and heteroaryl selected from thiazolyl and pyridyl, wherein said heteroaryl is substituted with 0 to 2 R d ;
• R d is, at each occurrence, independently selected from: F, Cl, CN, Ci-4 alkyl, Ci-4 alkoxy and Ci-4 haloalkyl;
• R e is independently selected from F, OH, OCH3, CHF2, and CF3.
• the invention provides a compound of Formula (Illg):
• R 2 is independently selected from -(CH2)2N(CI-4 alky 1)2, -(CH2)2--OR a ,
• R a is independently selected from: C1-4 alkyl substituted with from 0 to 2 F, , and heteroaryl selected from thiazolyl and pyridyl, wherein said heteroaryl is substituted with 0 to 2 R d ;
• R d is, at each occurrence, independently selected from: F, Cl, CN, C1-4 alkyl, Ci-4 alkoxy and C1-4 haloalkyl.
• the invention provides a compound of Formula (Illh):
• R 2 is independently selected from C1-4 alkyl, -(CH2)I-2CHF2, -(O3 ⁇ 4)2-40H, -CH 2 CH(CH3)(CH 2 )O-20H, -CH 2 CH(OH)CH 2 CH3, -(CH 2 )I-2C(CH3) 2 OH,
• the invention provides a compound of Formula (Illh): or a tautomer or a pharmaceutically acceptable salt thereof, wherein:
• R 2 is independently selected from -(CH2)2-40H, -CH2CH(CH3)(CH2)o-20H, -CH 2 CH(OH)CH 2 CH3, -(CH 2 )I-2C(CH3)20H, and -(CH 2 )20(CH 2 )I-20H; and
• R 3 is independently
• the invention provides a compound of Formula (Illh):
• R 2 is independently selected from C1-4 alkyl, -(CH2)I-2CHF2, -(CFh ⁇ OFl, -CH 2 CH(CH3)(CH 2 )I-20H, -(CH 2 )20(CH 2 )I-20H, -(CH 2 )2-40(CI-4 alkyl),
• the invention provides a compound of Formula (Illi):
• R 2 is independently selected from: -(CFh ⁇ OFl, -(CH2)2-40(CI-4 alkyl),
• R a is independently C 3 -6 cycloalkyl, , phenyl or heteroaryl selected from oxazolyl, isoxazolyl, thiazolyl, pyridyl and pyrazinyl, wherein said phenyl and heteroaryl are substituted with 0 to 2 R d ; and
• R d is, at each occurrence, independently selected from: F, Cl, CN, Ci-4 alkyl,
• Ci-4 alkoxy, and Ci-4 haloalkyl are examples of compounds that are identical to each other.
• the invention provides a compound of Formula (Illi):
• R 2 is independently -(CFh ⁇ OFl or -(CH2)2-40(CI-4 alkyl).
• the invention provides a compound selected from the exemplified examples or a stereoisomer, a tautomer or a pharmaceutically acceptable salt thereof.
• the invention provides a compound selected from the Examples 1 to 151 or a stereoisomer, a tautomer or a pharmaceutically acceptable salt thereof. In another aspect, the invention provides a compound selected from the Examples or a stereoisomer, a tautomer or a pharmaceutically acceptable salt thereof.
• the invention provides a compound selected from the Examples or a stereoisomer, a tautomer or a pharmaceutically acceptable salt thereof.
• the invention provides a compound selected from
• the invention provides a compound selected from
• the invention provides a compound selected from
• the invention provides a compound selected from
• the invention provides a compound selected from
• the invention provides a compound selected from
• the invention provides a compound selected from
• the invention provides a compound selected from
• the invention provides a compound selected from
• the invention provides a compound selected from
• the invention provides a compound selected from
• the present invention provides a compound selected from any subset list of compounds or a single compound from the exemplified examples within the scope of any of the above aspects.
• the invention provides a compound of Formula (Ila):
• the invention provides a compound of Formula (lib):
• the invention provides a compound of Formula (lie):
• the invention provides a compound of Formula (lid):
• the invention provides a compound of Formula (He):
• the invention provides a compound of Formula (Ilf):
• the invention provides a compound of Formula (Ilg):
• the invention provides a compound of Formula (Ilg-l):
• the invention provides a compound of Formula (Ilh):
• the invention provides a compound of Formula (Hi):
• R 1 is H or X-R 5 , wherein X is an unbranched Ci-6 alkylene, and R 5 is H, OH, cyano, Ci-4 alkoxy, Ci-4 haloalkoxy, -C(0)0R a , -NR b R c , or
• R 1 is H or halo. In other embodiments, R 1 is H. In other embodiments, R 1 is H or X-R 5 , wherein X is an unbranched Ci-6 alkylene, and R 5 is H, OH, cyano, Ci-4 alkoxy, Ci-4 haloalkoxy, -C(0)0R a , -NR b R c , or -C(0)NR b R k .
• R 1 is (Ci-3 alkylene)-aryl, wherein the aryl is substituted with 0 to 3 R d ; or (C1-3 alkylene)-heteroaryl including from 5 to 6 ring atoms, wherein from 1 to 4 ring atoms are each independently selected from N, N(R f ), O, and S, wherein the heteroaryl is substituted with 0 to 3 R d .
• R 1 is (C1-3 alkylene)-aryl, wherein the aryl is substituted with 0 to 3 R d .
• R 1 is (C1-3 alkylene)- heteroaryl including from 5 to 6 ring atoms, wherein from 1 to 4 ring atoms are each independently selected from N, N(R f ), O, and S, wherein the heteroaryl is substituted with 0 to 3 R d .
• R 1 is H, halo or C1-4 alkyl.
• R 1 is H, F or Ci-4 alkyl.
• R 2 is H, -Y-R 6 , or -C(0)-Y-R 6 ; wherein: Y is
• R 6 is, at each occurrence, independently: H, OH, OR a , -C(0)R a , -C(0)OR a , -NR b R c , -C(0)NR b R k , or heteroaryl including from 5 to 6 ring atoms, wherein from 1-4 ring atoms are each independently selected from N, N(R f ), O, and S, wherein the heteroaryl is substituted with from 0 to 3 R d .
• R 2 is -Y-R 6 , or -C(0)-Y-R 6 .
• R 2 is -Y-R 6 .
• R 2 is -(Y 1 ) n -Y 2 -(Y 3 )p-R 7 , wherein: each of n and p is independently 0 or 1; each of Y 1 and Y 3 is, independently, Ci-3 alkylene substituted with from 0 to 2 R e ; Y 2 is independently C3-6 cycloalkylene substituted with from 0 to 4 R g , or heterocycloalkylene including from 3-8 ring atoms, wherein from 1-2 ring atoms are each independently selected from N, N(R f ) and O, and wherein the heterocycloalkylene is substituted with from 0 to 4 R g , and R 7 is H, OH, -C(0)OR a , -NR b R c , -C(0)NR b R k , or heteroaryl including from 5-6 ring atoms, wherein from 1-4 ring atoms are each independently selected from N, N(R f ), O
• R 2 is -Z 1 -Z 2 -Z 3 -R 8 , wherein: Z 1 is C1-3 alkylene substituted with from 0 to 6 F; Z 2 is -h ⁇ R f )-, -O-, or -S-; Z 3 is C2-5 alkylene substituted with from 0 to 6 F; and R 8 is OH, OR a , -C(0)R a , -C(0)OR a ; -NR b R c , - C(0)NR b R k , or heteroaryl including from 5-6 ring atoms, wherein from 1-4 ring atoms are each independently selected from N, N(R f ), O, and S, wherein the heteroaryl is substituted with from 0 to 3 R d .
• R 2 is H, -(CH 2 )I -3 -R 6 , -(CH 2 )i-30(CH 2 ) 2-3 0R a , or
• R 2 is -(CH 2 )I -3 -R 6 , -(CH 2 )i-30(CH 2 ) 2-3 0R a , or -(CH 2 )I- 2 -Y 2 -R 7 .
• R 2 is -(CH 2 ) 2-3 -R 6 .
• R 2 is other embodiments, R 2 is
• R 3 is -(Co-3 alk lene)-(5-membered heteroaryl) wherein the heteroaryl includes 2 to 4 ring carbon atoms and 1 to 3 ring heteroatoms are each independently selected from: N, N(R f ), O, and S, and is substituted with 0 to 3 R g .
• R 3 is -(Co- 2 alkylene)-(5-membered heteroaryl) wherein the heteroaryl includes 2 to 4 ring carbon atoms and 1 to 3 ring heteroatoms are each independently selected from: N, N(R f ), O, and S, wherein the heteroaryl is substituted with from 0 to 2 R g .
• R 3 is 5-membered heteroaryl wherein the heteroaryl includes 3 to 4 ring carbon atoms and 1 to 2 ring heteroatoms are each
• R 3 is .
• R 4 is H, halo or Ci-4 alkyl. In other embodiments, R 4 is H, F or Ci-4 alkyl.
• R 6 is OH, OR a , -NR b R c , -C(0)NR b R k , or heteroaryl including from 5 to 6 ring atoms, wherein from 1 to 4 ring atoms are each independently selected from N, N(R f ), O, and S, wherein the heteroaryl is substituted with from 0 to 3 R d .
• R 6 is OH, OR a , NR b R c , -NR b C(0)R a , -C(0)NHR k , or heteroaryl including from 5 to 6 ring atoms, wherein from 1 to 4 ring atoms are each independently selected from N, N(R f ), O, and S, wherein the heteroaryl is substituted with from 0 to 3 R d .
• R 6 is OH, OR a , NR b R c , -NR b C(0)R a , -C(0)NH(Ci- 4 alkyl), -C(0)NHPh,
• R 6 is independently selected from: OH, OR a , N(CI-4 alkyl) 2 , -NR b C(0)R a , -C(0)NHPh,
• R 6 is OH, OR a , -NR b R c , or -C(0)NR b R k . In other embodiments, R 6 is -NR b R c , or -C(0)NR b R k .
• methods for modulating e.g., agonizing, partially agonizing, antagonizing
• NLRP3 activity include contacting NLRP3 with a chemical entity described herein (e.g., a compound described generically or specifically herein or a pharmaceutically acceptable salt thereof or compositions containing the same).
• methods for modulating NLRP3 activity are agonizing and partially agonizing.
• methods for modulating NLRP3 activity are agonizing.
• methods for modulating NLRP3 activity are partially agonizing.
• Methods include in vitro methods, e.g., contacting a sample that includes one or more cells comprising NLRP3 (e.g., THP-l cells) with the chemical entity.
• Methods can also include in vivo methods; e.g., administering the chemical entity to a subject (e.g., a human) having a disease in which an increase in NLRP3 signaling may correct a deficiency in innate immune activity that contributes to the pathology and/or symptoms and/or progression of the disease (e.g., cancer; e.g., a refractory cancer).
• compounds of the invention are useful for treating a condition, disease or disorder in which a decrease in NLRP3 activity (e.g., a condition, disease or disorder associated with repressed or impaired NLRP3 signaling) contributes to the pathology and/or symptoms and/or progression of the condition, disease or disorder (e.g., cancer) in a subject (e.g., a human).
• a condition, disease or disorder in which a decrease in NLRP3 activity e.g., a condition, disease or disorder associated with repressed or impaired NLRP3 signaling
• a subject e.g., a human
• a cancer is said to be refractory when it does not respond to (or is resistant to) cancer treatment.
• Refractory cancer is also known as resistant cancer.
• methods of treating cancer are featured that include
• the cancer may be a refractory cancer.
• methods of treatment of a disease in which an increase in NLRP3 signaling may correct a deficiency in innate immune activity that contributes to the pathology and/or symptoms and/or progression of the disease are featured that include administering to a subject in need of such treatment an effective amount of a chemical entity described herein (e.g., a compound described generically or specifically herein or a pharmaceutically acceptable salt thereof or compositions containing the same).
• a chemical entity described herein e.g., a compound described generically or specifically herein or a pharmaceutically acceptable salt thereof or compositions containing the same.
• methods of treatment include administering to a subject having a disease in which an increase in NLRP3 signaling may correct a deficiency in innate immune activity that contributes to the pathology and/or symptoms and/or progression of the disease an effective amount of a chemical entity described herein (e.g., a compound described generically or specifically herein or a
• methods of treatment include administering to a subject a chemical entity described herein (e.g., a compound described generically or specifically herein or a pharmaceutically acceptable salt thereof or compositions containing the same), wherein the chemical entity is administered in an amount effective to treat a disease in which an increase in NLRP3 signaling may correct a deficiency in innate immune activity that contributes to the pathology and/or symptoms and/or progression of the disease, thereby treating the disease.
• a chemical entity described herein e.g., a compound described generically or specifically herein or a pharmaceutically acceptable salt thereof or compositions containing the same
• Embodiments can include one or more of the following features.
• the chemical entity can be administered in combination with one or more additional cancer therapies (e.g., surgery, radiotherapy, chemotherapy, toxin therapy, immunotherapy, cryotherapy or gene therapy, or a combination thereof; e.g., cancer therapies that include administering one or more (e.g., two, three, four, five, six, or more) additional anti-cancer agents.
• additional cancer therapies e.g., surgery, radiotherapy, chemotherapy, toxin therapy, immunotherapy, cryotherapy or gene therapy, or a combination thereof; e.g., cancer therapies that include administering one or more (e.g., two, three, four, five, six, or more) additional anti-cancer agents.
• Non-limiting examples of additional anti-cancer agents are selected from an alkylating agent (e.g., cisplatin, carboplatin, mechlorethamine, cyclophosphamide, chlorambucil, ifosfamide and/or oxaliplatin); an anti-metabolite (e.g.,azathioprine and/or mercaptopurine); a terpenoid (e.g., a vinca alkaloid and/or a taxane; e.g., Vincristine, Vinblastine, Vinorelbine and/or Vindesine, Taxol, Paclitaxel and/or Docetaxel); a topoisomerase (e.g., a type I topoisomerase and/or a type 2 topoisomerase; e.g., camptothecins, such as irinotecan and/or topotecan;.
• an alkylating agent e.g.,
• a cytotoxic antibiotic e.g., actinomycin, anthracy dines, doxorubicin, daun
• Neuropilin, CD160, CD30, and CD155 e.g., CTLA-4 or PD1 or PD-L1
• immunomodulatory agents such as interleukin-2 (IL-2), indoleamine 2,3-dioxygenase
• IDO insulin receptor-associated antigen
• TGF transforming growth factor-b
• CD39 CD73 Adenosine-CD39- CD73
• the subject can have cancer; e.g., the subject has undergone and/or is undergoing and/or will undergo one or more cancer therapies.
• Non-limiting examples of cancer include acute myeloid leukemia, adrenocortical carcinoma, Kaposi sarcoma, lymphoma, anal cancer, appendix cancer, teratoid/rhabdoid tumor, basal cell carcinoma, bile duct cancer, bladder cancer, bone cancer, brain cancer, breast cancer, bronchial tumor, carcinoid tumor, cardiac tumor, cervical cancer, chordoma, chronic lymphocytic leukemia, chronic myeloproliferative neoplasm, colon cancer, colorectal cancer, craniopharyngioma, bile duct cancer, endometrial cancer, ependymoma, esophageal cancer, esthesioneuroblastoma, Ewing sarcoma, eye cancer, fallopian tube cancer, gallbladder cancer, gastrointestinal carcinoid tumor, gastrointestinal stromal tumor, germ cell tumor, hairy cell leukemia, head and neck cancer, heart cancer, liver cancer, hypophamge
• Merkel cell carcinoma mesothelioma, mouth cancer, oral cancer, osteosarcoma, ovarian cancer, penile cancer, pharyngeal cancer, prostate cancer, rectal cancer, salivary gland cancer, skin cancer, small intestine cancer, soft tissue sarcoma, testicular cancer, throat cancer, thyroid cancer, urethral cancer, uterine cancer, vaginal cancer, and vulvar cancer.
• the mammal has been identified as having a cancer or an infectious disease.
• infectious diseases include, without limitation, Acinobacter infection, actinomycosis, African sleeping sickness, acquired
• immunodeficiency syndrome amebiasis, anaplasmosis, anthrax, Arcanobacterium haemolyticum infection, Argentine hemorrhagic fever, ascariasis, aspergillosis, astrovirus infection, babesiosis, Bacillus cereus infection, bacterial pneumonia, bacterial vaginosis, Bacteroides infection, balantidiasis, Baylisascaris infection, BK virus infection, black piedra, Blastocystic hominis infection, blastomycosis, Venezuelan hemorrhagic fever, botulism, Brazilian hemorrhagic fever, brucellosis, bubonic plaque, Burkholderi infection, Buruli ulcer, Calicivirus infection, camptobacteriosis, candidiasis, cat-scratch disease, cellulitis, Chagas disease, chancroid, chickenpox, chikungunya, chlamydia, Chlamydophila
• the chemical entity can be administered intratumorally.
• the chemical entity can be administered systemically (including but not limited to orally, subcutaneously, intramuscular, intravenously).
• the methods can further include identifying the subject.
• references made in the singular may also include the plural.
• references made in the singular may also include the plural.
• “a” and “an” may refer to either one, or one or more.
• any heteroatom with unsatisfied valences is assumed to have hydrogen atoms sufficient to satisfy the valences.
• the symbol I— is used in formulas and tables to show the bond that is the point of attachment of the moiety or substituent to the core/nucleus of the structure.
• a substituent has a dash (-) that is not between two letters or symbols; this is used to indicate a point of attachment for a substituent.
• -OCFb is attached through the oxygen atom.
• NLRP3 is meant to include, without limitation, nucleic acids, polynucleotides, oligonucleotides, sense and antisense polynucleotide strands, complementary sequences, peptides, polypeptides, proteins, homologous and/or orthologous NLRP3 molecules, isoforms, precursors, mutants, variants, derivatives, splice variants, alleles, different species, and active fragments thereof.
• An "agonist" of NLRP3 includes compounds that, at the protein level, directly bind or modify NLRP3 such that an activity of NLRP3 is increased, e.g., by activation, stabilization, altered distribution, or otherwise.
• NLRP3 full agonist can function in assays as antagonists as well as agonists. These compounds antagonize activation ofNLRP3 by a NLRP3 full agonist because they prevent the full effect of NLRP3 interaction. However, the compounds also, on their own, activate some NLRP3 activity, typically less than a corresponding amount of the NLRP3 full agonist. Such compounds may be referred to as "partial agonists of NLRP3".
• the compounds described herein are agonists (e.g. full agonists) of NLRP3. In other embodiments, the compounds described herein are partial agonists of NLRP3.
• a receptor exists in an active (Ra) and an inactive (Ri) conformation.
• Certain compounds that affect the receptor can alter the ratio of Ra to Ri (Ra/Ri).
• a full agonist increases the ratio of Ra/Ri and can cause a "maximal", saturating effect.
• a partial agonist when bound to the receptor, gives a response that is lower than that elicited by a full agonist (e.g., an endogenous agonist).
• the Ra/Ri for a partial agonist is less than for a full agonist.
• the potency of a partial agonist may be greater or less than that of the full agonist.
• accepted with respect to a formulation, composition or ingredient, as used herein, means having no persistent detrimental effect on the general health of the subject being treated.
• API refers to an active pharmaceutical ingredient.
• ⁇ ективное amount refers to a sufficient amount of a chemical entity (e.g., a compound exhibiting activity as a mitochondrial uncoupling agent or a pharmaceutically acceptable salt and/or hydrate and/or cocrystal thereof; e.g., a compound, such as niclosamide or a
• an“effective amount” for therapeutic uses is the amount of the composition comprising a compound as disclosed herein required to provide a clinically significant decrease in disease symptoms.
• An appropriate“effective” amount in any individual case is determined using any suitable technique, such as a dose escalation study.
• excipient or“pharmaceutically acceptable excipient” means a pharmaceutically-acceptable material, composition, or vehicle, such as a liquid or solid filler, diluent, carrier, solvent, or encapsulating material.
• each component is“ pharmaceutically acceptable” in the sense of being compatible with the other ingredients of a pharmaceutical formulation, and suitable for use in contact with the tissue or organ of humans and animals without excessive toxicity, irritation, allergic response, immunogenicity, or other problems or complications, commensurate with a reasonable benefit/risk ratio. See, e.g., Remington: The Science and Practice of
• pharmaceutically acceptable salt refers to a formulation of a compound that does not cause significant irritation to an organism to which it is administered and does not abrogate the biological activity and properties of the compound.
• pharmaceutically acceptable salts are obtained by reacting a compound described herein, with acids such as hydrochloric acid, hydrobromic acid, sulfuric acid, nitric acid, phosphoric acid, methanesulfonic acid, ethanesulfonic acid, p-toluenesulfonic acid, salicylic acid and the like.
• pharmaceutically acceptable salts are obtained by reacting a compound having acidic group described herein with a base to form a salt such as an ammonium salt, an alkali metal salt, such as a sodium or a potassium salt, an alkaline earth metal salt, such as a calcium or a magnesium salt, a salt of organic bases such as dicyclohexylamine, /V-methyl-D-glucamine, tris(hydroxymethyl)methylamine, and salts with amino acids such as arginine, lysine, and the like, or by other methods previously determined.
• a salt such as an ammonium salt, an alkali metal salt, such as a sodium or a potassium salt, an alkaline earth metal salt, such as a calcium or a magnesium salt, a salt of organic bases such as dicyclohexylamine, /V-methyl-D-glucamine, tris(hydroxymethyl)methylamine, and salts with amino acids such as arginine, lysine, and the like, or by other
• Examples of a salt that the compounds described hereinform with a base include the following: salts thereof with inorganic bases such as sodium, potassium, magnesium, calcium, and aluminum; salts thereof with organic bases such as methylamine, ethylamine and ethanolamine; salts thereof with basic amino acids such as lysine and ornithine; and ammonium salt.
• the salts may be acid addition salts, which are specifically exemplified by acid addition salts with the following: mineral acids such as hydrochloric acid, hydrobromic acid, hydroiodic acid, sulfuric acid, nitric acid, and phosphoric acid: organic acids such as formic acid, acetic acid, propionic acid, oxalic acid, malonic acid, succinic acid, fumaric acid, maleic acid, lactic acid, malic acid, tartaric acid, citric acid, methanesulfonic acid, and ethanesulfonic acid; acidic amino acids such as aspartic acid and glutamic acid.
• mineral acids such as hydrochloric acid, hydrobromic acid, hydroiodic acid, sulfuric acid, nitric acid, and phosphoric acid
• organic acids such as formic acid, acetic acid, propionic acid, oxalic acid, malonic acid, succinic acid, fumaric acid, maleic acid, lactic acid, malic acid, tartaric
• pharmaceutical composition refers to a mixture of a compound described herein with other chemical components (referred to collectively herein as “excipients”), such as carriers, stabilizers, diluents, dispersing agents, suspending agents, and/or thickening agents.
• excipients such as carriers, stabilizers, diluents, dispersing agents, suspending agents, and/or thickening agents.
• the pharmaceutical composition facilitates administration of the compound to an organism. Multiple techniques of administering a compound exist in the art including, but not limited to: rectal, oral, intravenous, aerosol, parenteral, ophthalmic, pulmonary, and topical administration.
• subject refers to an animal, including, but not limited to, a primate (e.g., human), monkey, cow, pig, sheep, goat, horse, dog, cat, rabbit, rat, or mouse.
• the terms“subject” and“patient” are used interchangeably herein in reference, for example, to a mammalian subject, such
• treat in the context of treating a disease or disorder, are meant to include alleviating or abrogating a disorder, disease, or condition, or one or more of the symptoms associated with the disorder, disease, or condition; or to slowing the progression, spread or worsening of a disease, disorder or condition or of one or more symptoms thereof.
• The“treatment of cancer” refers to one or more of the following effects: (1) inhibition, to some extent, of tumor growth, including, (i) slowing down and (ii) complete growth arrest; (2) reduction in the number of tumor cells; (3) maintaining tumor size; (4) reduction in tumor size; (5) inhibition, including (i) reduction, (ii) slowing down or (iii) complete prevention, of tumor cell infiltration into peripheral organs; (6) inhibition, including (i) reduction, (ii) slowing down or (iii) complete prevention, of metastasis; (7) enhancement of anti-tumor immune response, which may result in (i) maintaining tumor size, (ii) reducing tumor size, (iii) slowing the growth of a tumor, (iv) reducing, slowing or preventing invasion and/or (8) relief, to some extent, of the severity or number of one or more symptoms associated with the disorder.
• halo refers to fluoro (F), chloro (Cl), bromo (Br), or iodo (I).
• alkyl refers to a hydrocarbon chain that may be a straight chain or branched chain, containing the indicated number of carbon atoms.
• Ci-io indicates that the group may have from 1 to 10 (inclusive) carbon atoms in it.
• Non- limiting examples include methyl, ethyl, /.sopropyh /er/-butyl, «-hexyl.
• alkylene refers to a branched or unbranched divalent alkyl (e.g.,
• haloalkyl refers to an alkyl, in which one or more hydrogen atoms is/are replaced with an independently selected halo.
• alkoxy refers to an -O-alkyl radical (e.g., -OCFb).
• haloalkoxy refers to an— O-haloalkyl group as defined above with the indicated number of carbon atoms attached through an oxygen bridge.
• Ci-6 haloalkoxy is intended to include Ci, C2, C3, C 4 , C5, and Ce haloalkoxy groups.
• haloalkoxy include, but are not limited to, trifluoromethoxy,
• alkenyl refers to a hydrocarbon chain that may be a straight chain or branched chain having one or more carbon-carbon double bonds.
• the alkenyl moiety contains the indicated number of carbon atoms. For example, C2-6 indicates that the group may have from 2 to 6 (inclusive) carbon atoms in it.
• alkynyl refers to a hydrocarbon chain that may be a straight chain or branched chain having one or more carbon-carbon triple bonds.
• the alkynyl moiety contains the indicated number of carbon atoms. For example, C2-6 indicates that the group may have from 2 to 6 (inclusive) carbon atoms in it.
• aromatic refers generally to a ring that includes a cyclic array of resonance-stabilized 4n + 2 pi electrons, wherein n is an integer (e.g., 1 or 2).
• Aromatic moieties include aryl and heteroaryl groups.
• nonaromatic describes any moiety that does not fall within the definition of“aromatic”.
• aryl refers to a 6-carbon monocyclic, 10-carbon bicyclic, or 14-carbon tricyclic aromatic ring system wherein 0, 1, 2, 3, or 4 atoms of each ring may be substituted by a substituent, and wherein the ring comprising a monocyclic radical is aromatic and wherein at least one of the fused rings comprising a bicyclic or tricyclic radical is aromatic e.g. tetrahydronaphthyl. Examples of aryl groups also include phenyl, naphthyl and the like.
• cycloalkyl as used herein includes saturated cyclic hydrocarbon groups having 3 to 10 carbons, preferably 3 to 8 carbons, and more preferably 3 to 6 carbons, wherein the cycloalkyl group may be optionally substituted.
• Preferred cycloalkyl groups include, without limitation, cyclopropyl, cyclobutyl, cyclopentyl, cyclopentenyl, cyclohexyl, cyclohexenyl, cycloheptyl, and cyclooctyl.
• cycloalkylene as used herein refers to divalent cycloalkyl.
• heteroaryl refers to an aromatic 5-8 membered monocyclic, 8-12 membered bicyclic, or 11-14 membered tricyclic ring system having 1-3 heteroatoms if monocyclic, 1-6 heteroatoms if bicyclic, or 1-9 heteroatoms if tricyclic, said heteroatoms selected from O, N, or S (e.g., carbon atoms and 1-3, 1-6, or 1-9 heteroatoms of N, O, or S if monocyclic, bicyclic, or tricyclic, respectively), wherein 0, 1, 2, 3, or 4 atoms of each ring may be substituted by a substituent, and wherein the ring comprising a monocyclic radical is aromatic and wherein at least one of the fused rings comprising a bicyclic or tricyclic radical is aromatic (but does not have to be a ring which contains a heteroatom, e.g.
• heteroaryl groups also include pyridyl, furyl or furanyl, imidazolyl, benzimidazolyl, pyrimidinyl, thiophenyl or thienyl, quinolinyl, indolyl, thiazolyl, and the like.
• heterocyclyl refers to a nonaromatic 5-8 membered monocyclic, 7-12 membered bicyclic or bridged, or 11-14 membered tricyclic ring system having 1-3 heteroatoms if monocyclic, 1-6 heteroatoms if bicyclic, spiro, or bridged, or 1-9 heteroatoms if tricyclic, said heteroatoms selected from O, N, or S (e.g., carbon atoms and 1-3, 1-6, or 1-9 heteroatoms of N, O, or S if monocyclic, bicyclic, or tricyclic, respectively), wherein 0, 1, 2 or 3 atoms of each ring may be substituted by a substituent.
• heterocyclyl groups include piperazinyl, pyrrolidinyl, dioxanyl, morpholinyl, tetrahydrofuranyl, and the like.
• heterocycloalkylene refers to divalent heterocyclyl.
• atoms making up the compounds of the present embodiments are intended to include all isotopic forms of such atoms.
• Isotopes include those atoms having the same atomic number but different mass numbers.
• isotopes of hydrogen include tritium and deuterium
• isotopes of carbon include 13 C and 14 C.
• This disclosure features chemical entities (e.g., a compound or a pharmaceutically acceptable salt, and/or hydrate, and/or cocrystal, and/or drug combination of the compound) that modulate (e.g., agonizes or partially agonizes) NLRP3 that are useful, e.g., for treating a condition, disease or disorder in which an increase in NLRP3 signaling may correct a deficiency in innate immune activity (e.g., a condition, disease or disorder associated with an insufficient immune response) that contributes to the pathology and/or symptoms and/or progression of the condition, disease or disorder (e.g., cancer) in a subject (e.g., a human).
• This disclosure also features compositions as well as other methods of using and making the same.
• a chemical entity e.g., a compound that modulates (e.g., agonizes or partially agonizes) NLRP3, or a pharmaceutically acceptable salt, and/or hydrate, and/or cocrystal, and/or drug combination thereof) is administered as a pharmaceutical composition that includes the chemical entity and one or more pharmaceutically acceptable excipients, and optionally one or more additional therapeutic agents as described herein.
• a pharmaceutical composition that includes the chemical entity and one or more pharmaceutically acceptable excipients, and optionally one or more additional therapeutic agents as described herein.
• a pharmaceutical composition comprising a compound of the present invention or a salt thereof, and one or more pharmaceutically acceptable excipients. In certain embodiments, a pharmaceutical composition comprising a compound of the present invention or a pharmaceutically acceptable salt thereof, and one or more pharmaceutically acceptable excipients. In certain embodiments, a pharmaceutical composition comprising a compound of the present invention or a pharmaceutically acceptable salt thereof, and one or more pharmaceutically acceptable excipients. In certain embodiments, a
• composition comprising a therapeutically effective amount of a compound of the present invention or a pharmaceutically acceptable salt thereof, and one or more pharmaceutically acceptable excipients.
• the chemical entities can be administered in combination with one or more conventional pharmaceutical excipients.
• Pharmaceutically acceptable excipients include, but are not limited to, ion exchangers, alumina, aluminum stearate, lecithin, self-emulsifying drug delivery systems (SEDDS) such as d-a-tocopherol polyethylene glycol 1000 succinate, surfactants used in pharmaceutical dosage forms such as Tweens, poloxamers or other similar polymeric delivery matrices, serum proteins, such as human serum albumin, buffer substances such as phosphates, tris, glycine, sorbic acid, potassium sorbate, partial glyceride mixtures of saturated vegetable fatty acids, water, salts or electrolytes, such as protamine sulfate, disodium hydrogen phosphate, potassium hydrogen phosphate, sodium-chloride, zinc salts, colloidal silica, magnesium trisilicate, polyvinyl pyrrolidone, cellulose-based substances, polyethylene glycol, sodium, sodium
• Cyclodextrins such as a-, b, and g-cyclodextrin, or chemically modified derivatives such as hydroxyalkylcyclodextrins, including 2- and 3- hydroxy propyl-P-cy cl odextrins. or other solubilized derivatives can also be used to enhance delivery of compounds described herein.
• Dosage forms or compositions containing a chemical entity as described herein in the range of 0.005% to 100% with the balance made up from non-toxic excipient may be prepared.
• the contemplated compositions may contain 0.001 %-l 00% of a chemical entity provided herein, in one embodiment 0.1-95%, in another embodiment 75-85%, in a further embodiment 20-80%. Actual methods of preparing such dosage forms are known, or will be apparent, to those skilled in this art; for example, s QQ Remington: The Science and Practice of Pharmacy, 22 nd Edition (Pharmaceutical Press, London, UK. 2012).
• the chemical entities described herein or a pharmaceutical composition thereof can be administered to subject in need thereof by any accepted route of administration.
• Acceptable routes of administration include, but are not limited to, buccal, cutaneous, endocervical, endosinusial, endotracheal, enteral, epidural, interstitial, intra-abdominal, intra-arterial, intrabronchial, intrabursal, intracerebral, intracistemal, intracoronary, intradermal, intraductal, intraduodenal, intradural, intraepidermal, intraesophageal, intragastric, intragingival, intraileal, intralymphatic, intramedullary, intrameningeal, intramuscular, intraovarian, intraperitoneal, intraprostatic,
• a preferred route of administration is parenteral (e.g., intratumoral).
• administration is systemic.
• compositions can be formulated for parenteral administration, e.g., formulated for injection via the intravenous, intramuscular, sub-cutaneous, or even intraperitoneal routes.
• parenteral administration e.g., formulated for injection via the intravenous, intramuscular, sub-cutaneous, or even intraperitoneal routes.
• such compositions can be prepared as injectables, either as liquid solutions or suspensions; solid forms suitable for use to prepare solutions or suspensions upon the addition of a liquid prior to injection can also be prepared; and the preparations can also be emulsified.
• injectables either as liquid solutions or suspensions
• solid forms suitable for use to prepare solutions or suspensions upon the addition of a liquid prior to injection can also be prepared; and the preparations can also be emulsified.
• the preparation of such formulations will be known to those of skill in the art in light of the present disclosure.
• the pharmaceutical forms suitable for injectable use include sterile aqueous solutions or dispersions; formulations including sesame oil, peanut oil, or aqueous propylene glycol; and sterile powders for the extemporaneous preparation of sterile injectable solutions or dispersions.
• the form must be sterile and must be fluid to the extent that it may be easily injected. It also should be stable under the conditions of manufacture and storage and must be preserved against the contaminating action of microorganisms, such as bacteria and fungi.
• the carrier also can be a solvent or dispersion medium containing, for example, water, ethanol, polyol (for example, glycerol, propylene glycol, and liquid polyethylene glycol, and the like), suitable mixtures thereof, and vegetable oils.
• the proper fluidity can be maintained, for example, by the use of a coating, such as lecithin, by the maintenance of the required particle size in the case of dispersion, and by the use of surfactants.
• the prevention of the action of microorganisms can be brought about by various antibacterial and antifungal agents, for example, parabens, chlorobutanol, phenol, sorbic acid, thimerosal, and the like.
• isotonic agents for example, sugars or sodium chloride.
• Prolonged absorption of the injectable compositions can be brought about by the use in the compositions of agents delaying absorption, for example, aluminum monostearate and gelatin.
• Sterile injectable solutions are prepared by incorporating the active compounds in the required amount in the appropriate solvent with various of the other ingredients enumerated above, as required, followed by filtered sterilization.
• dispersions are prepared by incorporating the various sterilized active ingredients into a sterile vehicle which contains the basic dispersion medium and the required other ingredients from those enumerated above.
• the preferred methods of preparation are vacuum-drying and freeze-drying techniques, which yield a powder of the active ingredient, plus any additional desired ingredient from a previously sterile-filtered solution thereof.
• Pharmacologically acceptable excipients usable in the rectal composition as a gel, cream, enema, or rectal suppository include, without limitation, any one or more of cocoa butter glycerides, synthetic polymers such as polyvinylpyrrolidone, PEG (like PEG ointments), glycerine, glycerinated gelatin, hydrogenated vegetable oils, poloxamers, mixtures of polyethylene glycols of various molecular weights and fatty acid esters of polyethylene glycol Vaseline, anhydrous lanolin, shark liver oil, sodium saccharinate, menthol, sweet almond oil, sorbitol, sodium benzoate, anoxid SBN, vanilla essential oil, aerosol, parabens in phenoxy ethanol, sodium methyl p-oxybenzoate, sodium propyl
• suppositories can be prepared by mixing the chemical entities described herein with suitable non-irritating excipients or carriers such as cocoa butter, polyethylene glycol or a suppository wax which are solid at ambient temperature but liquid at body temperature and therefore melt in the rectum and release the active compound.
• suitable non-irritating excipients or carriers such as cocoa butter, polyethylene glycol or a suppository wax which are solid at ambient temperature but liquid at body temperature and therefore melt in the rectum and release the active compound.
• compositions for rectal administration are in the form of an enema.
• the compounds described herein or a pharmaceutical composition thereof are suitable for local delivery to the digestive or GI tract by way of oral administration (e.g., solid or liquid dosage forms.).
• Solid dosage forms for oral administration include capsules, tablets, pills, powders, and granules.
• the chemical entity is mixed with one or more pharmaceutically acceptable excipients, such as sodium citrate or dicalcium phosphate and/or: a) fillers or extenders such as starches, lactose, sucrose, glucose, mannitol, and silicic acid, b) binders such as, for example, carboxymethylcellulose, alginates, gelatin, polyvinylpyrrolidinone, sucrose, and acacia, c) humectants such as glycerol, d) disintegrating agents such as agar-agar, calcium carbonate, potato or tapioca starch, alginic acid, certain silicates, and sodium carbonate, e) solution retarding agents such as paraffin, f) absorption accelerators such as quaternary ammonium compounds, g) wetting agents such as, for example, cetyl alcohol and glycerol mono
• the dosage form may also comprise buffering agents.
• Solid compositions of a similar type may also be employed as fillers in soft and hard-filled gelatin capsules using such excipients as lactose or milk sugar as well as high molecular weight polyethylene glycols and the like.
• the compositions will take the form of a unit dosage form such as a pill or tablet and thus the composition may contain, along with a chemical entity provided herein, a diluent such as lactose, sucrose, dicalcium phosphate, or the like; a lubricant such as magnesium stearate or the like; and a binder such as starch, gum acacia, polyvinylpyrrolidine, gelatin, cellulose, cellulose derivatives or the like.
• a diluent such as lactose, sucrose, dicalcium phosphate, or the like
• a lubricant such as magnesium stearate or the like
• a binder such as starch, gum acacia, polyvinylpyrrolidine, gelatin, cellulose, cellulose derivatives or the like.
• a powder, marume, solution or suspension (e.g., in propylene carbonate, vegetable oils, PEG’S, poloxamer 124 or triglycerides) is encapsulated in a capsule (gelatin or cellulose base capsule).
• Unit dosage forms in which one or more chemical entities provided herein or additional active agents are physically separated are also contemplated; e.g., capsules with granules (or tablets in a capsule) of each drug; two-layer tablets; two-compartment gel caps, etc. Enteric coated or delayed release oral dosage forms are also contemplated.
• physiologically acceptable compounds include wetting agents, emulsifying agents, dispersing agents or preservatives that are particularly useful for preventing the growth or action of microorganisms.
• Various preservatives are well known and include, for example, phenol and ascorbic acid.
• the excipients are sterile and generally free of undesirable matter. These compositions can be sterilized by conventional, well-known sterilization techniques. For various oral dosage form excipients such as tablets and capsules sterility is not required. The USP/NF standard is usually sufficient.
• solid oral dosage forms can further include one or more components that chemically and/or structurally predispose the composition for delivery of the chemical entity to the stomach or the lower GI; e.g., the ascending colon and/or transverse colon and/or distal colon and/or small bowel.
• Exemplary formulation techniques are described in, e.g., Filipski, K.J., et al, Current Topics in Medicinal Chemistry, 2013, 13, 776-802, which is incorporated herein by reference in its entirety.
• Examples include upper-GI targeting techniques, e.g., Accordion Pill (Intec Pharma), floating capsules, and materials capable of adhering to mucosal walls.
• Upper-GI targeting techniques e.g., Accordion Pill (Intec Pharma)
• floating capsules e.g., floating capsules, and materials capable of adhering to mucosal walls.
• enteric/pH-responsive coatings and excipients are available. These materials are typically polymers that are designed to dissolve or erode at specific pH ranges, selected based upon the GI region of desired drug release. These materials also function to protect acid labile drugs from gastric fluid or limit exposure in cases where the active ingredient may be irritating to the upper GI (e.g., hydroxypropyl methylcellulose phthalate series, Coateric (polyvinyl acetate phthalate), cellulose acetate phthalate, hydroxypropyl methylcellulose acetate succinate, Eudragit series (methacrylic acid-methyl methacrylate copolymers), and Marcoat).
• Other techniques include dosage forms that respond to local flora in the GI tract, Pressure-controlled colon delivery capsule, and Pulsincap.
• Ocular compositions can include, without limitation, one or more of any of the following: viscogens (e.g., Carboxymethylcellulose, Glycerin, Polyvinylpyrrolidone, Polyethylene glycol); Stabilizers (e.g., Pluronic (triblock copolymers), Cyclodextrins); Preservatives (e.g., Benzalkonium chloride, ETDA, SofZia (boric acid, propylene glycol, sorbitol, and zinc chloride; Alcon Laboratories, Inc.), Purite (stabilized oxychloro complex; Allergan, Inc.)).
• viscogens e.g., Carboxymethylcellulose, Glycerin, Polyvinylpyrrolidone, Polyethylene glycol
• Stabilizers e.g., Pluronic (triblock copolymers), Cyclodextrins
• Preservatives e.g., Benzalkonium chloride, ETDA, SofZ
• Topical compositions can include ointments and creams.
• Ointments are semisolid preparations that are typically based on petrolatum or other petroleum derivatives.
• Creams containing the selected active agent are typically viscous liquid or semisolid emulsions, often either oil-in-water or water-in-oil.
• Cream bases are typically water- washable, and contain an oil phase, an emulsifier and an aqueous phase.
• the oil phase also sometimes called the“internal” phase, is generally comprised of petrolatum and a fatty alcohol such as cetyl or stearyl alcohol; the aqueous phase usually, although not necessarily, exceeds the oil phase in volume, and generally contains a humectant.
• the emulsifier in a cream formulation is generally a nonionic, anionic, cationic or amphoteric surfactant.
• an ointment base should be inert, stable, nonirritating and non-sensitizing.
• compositions described herein can include one or more one or more of the following: lipids, interbilayer crosslinked multilamellar vesicles, biodegradeable poly(D,L-lactic-co-gly colic acid) [PLGA] -based or poly anhydride-based nanoparticles or microparticles, and nanoporous particle-supported lipid bilayers.
• the dosages may be varied depending on the requirement of the patient, the severity of the condition being treating and the particular compound being employed. Determination of the proper dosage for a particular situation can be determined by one skilled in the medical arts.
• the total daily dosage may be divided and administered in portions throughout the day or by means providing continuous delivery.
• the compounds described herein are administered at a dosage of from about 0.001 mg/Kg to about 500 mg/Kg (e.g., from about 0.001 mg/Kg to about 200 mg/Kg; from about 0.01 mg/Kg to about 200 mg/Kg; from about 0.01 mg/Kg to about 150 mg/Kg; from about 0.01 mg/Kg to about 100 mg/Kg; from about 0.01 mg/Kg to about 50 mg/Kg; from about 0.01 mg/Kg to about 10 mg/Kg; from about 0.01 mg/Kg to about 5 mg/Kg; from about 0.01 mg/Kg to about 1 mg/Kg; from about 0.01 mg/Kg to about 0.5 mg/Kg; from about 0.01 mg/Kg to about 0.1 mg/Kg; from about 0.
• the foregoing dosages can be administered on a daily basis (e.g., as a single dose or as two or more divided doses) or non-daily basis (e.g., every other day, every two days, every three days, once weekly, twice weeks, once every two weeks, once a month).
• a daily basis e.g., as a single dose or as two or more divided doses
• non-daily basis e.g., every other day, every two days, every three days, once weekly, twice weeks, once every two weeks, once a month.
• the period of administration of a compound described herein is for 1 day, 2 days, 3 days, 4 days, 5 days, 6 days, 7 days, 8 days, 9 days, 10 days, 1 1 days, 12 days, 13 days, 14 days, 3 weeks, 4 weeks, 5 weeks, 6 weeks, 7 weeks, 8 weeks, 9 weeks, 10 weeks, 11 weeks, 12 weeks, 4 months, 5 months, 6 months, 7 months, 8 months, 9 months, 10 months, 1 1 months, 12 months, or more.
• a period of during which administration is stopped is for 1 day, 2 days, 3 days, 4 days, 5 days, 6 days, 7 days, 8 days, 9 days, 10 days, 1 1 days, 12 days, 13 days,
• a therapeutic compound is administered to an individual for a period of time followed by a separate period of time.
• a therapeutic compound is administered for a first period and a second period following the first period, with administration stopped during the second period, followed by a third period where administration of the therapeutic compound is started and then a fourth period following the third period where administration is stopped.
• the period of administration of a therapeutic compound followed by a period where administration is stopped is repeated for a determined or undetermined period of time.
• a period of administration is for 1 day, 2 days, 3 days, 4 days, 5 days, 6 days, 7 days, 8 days, 9 days, 10 days, 11 days, 12 days, 13 days, 14 days, 3 weeks, 4 weeks, 5 weeks, 6 weeks, 7 weeks, 8 weeks, 9 weeks, 10 weeks, 11 weeks, 12 weeks, 4 months, 5 months, 6 months,
• a period of during which administration is stopped is for 1 day, 2 days, 3 days, 4 days, 5 days, 6 days, 7 days, 8 days, 9 days, 10 days, 11 days, 12 days, 13 days, 14 days, 3 weeks, 4 weeks, 5 weeks, 6 weeks, 7 weeks, 8 weeks, 9 weeks, 10 weeks, 11 weeks, 12 weeks, 4 months, 5 months, 6 months, 7 months, 8 months, 9 months, 10 months, 11 months, 12 months, or more.
• methods for treating a subject having condition, disease or disorder in which an increase in NLRP3 signaling may correct a deficiency in innate immune activity e.g., a condition, disease or disorder associated with an insufficient immune response
• a deficiency in innate immune activity e.g., a condition, disease or disorder associated with an insufficient immune response
• contributes to the pathology and/or symptoms and/or progression of the condition, disease or disorder e.g., cancer
• the subject can have a cancer.
• the mammal has been identified as having a cancer, or has been diagnosed as having a cancer.
• Non-limiting examples of cancer include: acute myeloid leukemia, adrenocortical carcinoma, Kaposi sarcoma, lymphoma, anal cancer, appendix cancer, teratoid/rhabdoid tumor, basal cell carcinoma, bile duct cancer, bladder cancer, bone cancer, brain cancer, breast cancer, bronchial tumor, carcinoid tumor, cardiac tumor, cervical cancer, chordoma, chronic lymphocytic leukemia, chronic myeloproliferative neoplasm, colon cancer, colorectal cancer, craniopharyngioma, bile duct cancer, endometrial cancer, ependymoma, esophageal cancer, esthesioneuroblastoma, Ewing sarcoma, eye cancer, fallopian tube cancer, gallbladder cancer, gastrointestinal carcinoid tumor, gastrointestinal stromal tumor, germ cell tumor, hairy cell leukemia, head and neck cancer, heart cancer, liver cancer, hypopham
• Merkel cell carcinoma mesothelioma, mouth cancer, oral cancer, osteosarcoma, ovarian cancer, penile cancer, pharyngeal cancer, prostate cancer, rectal cancer, salivary gland cancer, skin cancer, small intestine cancer, soft tissue sarcoma, testicular cancer, throat cancer, thyroid cancer, urethral cancer, uterine cancer, vaginal cancer, and vulvar cancer.
• non-limiting examples of cancer include: breast cancer, colon cancer, rectal cancer, colorectal cancer, pancreatic cancer, and prostate cancer.
• a medical professional e.g., a physician, a physician’s assistant, or a technician
• Non-limiting examples of symptoms of cancer include: fatigue, lump or area of thickening felt under the skin, weight change, jaundice, darkening or redness of the skin, sores that won’t heal, changes to existing moles, changes in bowel or bladder habits, persistent cough or trouble breathing, difficulty swallowing, hoarseness, persistent indigestion or discomfort after eating, persistent, unexplained muscle or joint pain, persistent, unexplained fevers or night sweats, and unexplained bleeding or bruising.
• Methods of diagnosing a subject as having a cancer or identifying a subject as having a cancer can further include performing one or more diagnostic tests (e.g., performing one or more diagnostic tests on a biopsy or a blood sample).
• a subject can be a subject having a cancer, a subject diagnosed as having a cancer, or a subject identified as having a cancer that has been unresponsive to a previously administered treatment for cancer. Diagnostic tests for diagnosing a subject as having a cancer or identifying a mammal as having a cancer are known in the art.
• methods for treating a subject having condition, disease or disorder in which an increase in NLRP3 signaling may correct a deficiency in innate immune activity e.g., a condition, disease or disorder associated with an insufficient immune response
• a deficiency in innate immune activity e.g., a condition, disease or disorder associated with an insufficient immune response
• contributes to the pathology and/or symptoms and/or progression of the condition, disease or disorder e.g., cancer
• the present invention provides a method of treating cancer, wherein the cancer can be any cancer that does not elicit an optimal innate immune system response.
• Innate immune system refers to a part of the immune system consisting of cells that react to threats for the organism like infections or cancer in an antigen-non-specific way and stimulate the adaptive, antigen-specific immune system.
• complete removal of the threat and long-lasting protection requires activity of the adaptive, antigen-specific immune system that in turn depends on stimulation by the innate immune system.
• the present invention provides a method of treating case, the cancer is selected based on resistance to T-cell checkpoint inhibition, either independent of cancer type and based on failure to respond to previous T-cell checkpoint inhibitor therapy or based on cancer type that is generally resistant to T-cell checkpoint inhibitor therapy such as hormone receptor positive breast cancer, microsatellite stable colon or rectal cancer, pancreatic cancer and prostate cancer.
• the present invention provides a method of treating cancer comprising an NLPR3 agonist of the present invention to treat non-inflamed tumors with low CD8+ T-cell infiltration to enhance tumor immunogenicity and promote inflammatory responses.
• the combination may be used to treat a solid tumor based on results of a biopsy that demonstrated low CD 8+ T-cell infiltration or low expression of genes produced by CD8+ T-cells.
• Resistance to T-cell checkpoint inhibition refers to cancer progression on therapy or lack of response within 6 months of therapy according to consensus response criteria for the respective cancer, such as RECIST1.1 for most solid tumors.
• T-cell infiltration refers to percent of T-cells of all nucleated cells by
• CD8+ T-cell infiltration refers to percent of CD8+ cells of all nucleated cells by immunohistochemistry of tumor biopsy specimens.
• CD8+ T-cells In addition to immunohistochemistry for quantifying CD8+ T-cells in biopsy specimens, expression of genes produced by CD 8+ T-cells like interferon-g can be measured by quantifying mRNA using for example next generation sequencing and inform about CD8+ T-cell infiltration. Thresholds for low and high CD8+ T-cell infiltration by immunohistochemistry of mRNA quantifying techniques are being developed by various groups and take the spectrum of CD8+ T-cell infiltration across cancers as well as for specific cancers into account.
• the subject can have an infectious disease.
• the subject has been identified as having an infectious disease, or has been diagnosed as having an infectious disease.
• an infectious disease can be caused by a bacterium, virus, fungus, parasite, or a mycobacterium.
• Non-limiting examples of infectious disease include: Acinobacter infection, actinomycosis, African sleeping sickness, acquired immunodeficiency syndrome, amebiasis, anaplasmosis, anthrax, Arcanobacterium haemolyticum infection, Argentine hemorrhagic fever, ascariasis, aspergillosis, astrovirus infection, babesiosis, Bacillus cereus infection, bacterial pneumonia, bacterial vaginosis, Bacteroides infection, balantidiasis, Baylisascaris infection, BK virus infection, black piedra, Blastocystic hominis infection, blastomycosis, Venezuelan hemorrhagic fever, botulism, Brazilian hemorrhagic fever, brucellosis, bubonic plaque, Burkholderi infection, Buruli ulcer, Calicivirus infection, camptobacteriosis, candidiasis, cat-scratch disease, cellulitis, Chagas disease, chancroid
• Group B streptococcal infection Haemophilus influenzae infection, hand foot and mouth disease, hantavirus pulmonary syndrome, Heartland virus disease, Heliobacter pylori infection, hemolytic-uremic syndrome, hemorrhagic fever with renal syndrome, hepatitis A, hepatitis B, hepatitis C, hepatitis D, hepatitis E, herpes simplex, histoplasmosis, hookworm infection, human bocavirus infection, human ewingii ehrlichiosis, human granulocyte anaplasmosis, human metapneuomovirus infection, human monocytic ehrlichiosis, human papillomavirus infection, human parainfluenza virus infection, hymenolepiasis, Epstein-Barr virus infectious mononucleosis, influenza, isosporiasis, Kawasaki disease, keratitis, Kingella kingae infection, kuru, lassa fever
• leukoencephalopathy psittacosis, Q fever, rabies, relapsing fever, respiratory syncytial virus infection, rhinosporidiosis, rhinovirus infection, rickettsial infection, rickettsialpox, Rift Valley Fever, Rocky Mountain spotted fever, rotavirus infection, rubella, salmonellosis, severe acute respiratory syndrome, scabies, schistosomiasis, sepsis, shigellosis, shingles, smallpox, sporothrichosis, staphylococcal food poisoning, staphylococcal infection, strongyloidiasis, subacute sclerosing panencephalitis, syphilis, taeniasis, tetanus, tinea barabe, tinea capitis, tinea corporis, tinea cruris, tinea manum, tinea nigra, tinea pedis, tinea unguium, tinea versicolor, tox
• Methods for diagnosing a subject as having an infectious disease, or identifying a subject as having an infectious disease are well known in the art.
• a medical professional e.g., a physician, a physician’s assistant, or a technician
• symptoms of infectious disease include: fever, diarrhea, fatigue, and muscle aches.
• Methods of diagnosing a mammal as having an infectious disease or identifying a subject as having an infectious disease can further include performing one or more diagnostic tests (e.g., performing one or more diagnostic tests on a biopsy or a blood sample). Diagnostic tests for diagnosing a subject as having an infectious disease or identifying a subject as having an infectious disease are known in the art.
• This disclosure contemplates both monotherapy regimens as well as combination therapy regimens.
• the methods described herein can further include administering one or more additional therapies (e.g., one or more additional therapeutic agents and/or one or more therapeutic regimens) in combination with administration of the compounds described herein.
• additional therapies e.g., one or more additional therapeutic agents and/or one or more therapeutic regimens
• the methods described herein can further include administering one or more additional cancer therapies.
• the one or more additional cancer therapies can include, without limitation, surgery, radiotherapy, chemotherapy, toxin therapy, immunotherapy, cryotherapy, cancer vaccines (e.g., HPV vaccine, hepatitis B vaccine, Oncophage, Provenge) and gene therapy, as well as combinations thereof.
• Immunotherapy including, without limitation, adoptive cell therapy, the derivation of stem cells and/or dendritic cells, blood
• transfusions including, without limitation, freezing a tumor.
• the one or more additional cancer therapies is
• chemotherapy which can include administering one or more additional chemotherapeutic agents.
• the additional cancer therapy comprises
• an immunomodulatory moiety e.g., an immune checkpoint inhibitor.
• the immune checkpoint inhibitor targets an immune checkpoint receptor selected from CTLA-4, PD-l, PD-L1, PD-l - PD-L1, PD-l
• T cell immunoglobulin and mucin 3 TIM3 or HAVCR2
• Galectin 9 - TIM3 Phosphatidylserine - TIM3, lymphocyte activation gene 3 protein (LAG3)
• LAG3 lymphocyte activation gene 3 protein
• ICOS ICOS, ICOS-ICOS ligand, B7-H3, B7-H4, VISTA, TMIGD2, HHLA2-TMIGD2,
• Butyrophilins including BTNL2, Siglec family, TIGIT and PVR family members, KIRs, ILTs and LIRs, NKG2D and NKG2A, MICA and MICB, CD244, CD28, CD86 - CD28, CD86 - CTLA, CD80 - CD28, Phosphatidylserine, TIM3, Phosphatidylserine - TIM3, SIRPA-CD47, VEGF, Neuropilin, CD160, CD30, and CD155 (e.g., CTLA-4 or PD1 or
• PD-L1 PD-L1
• immunomodulatory agents such as interleukin-2 (IL-2), indoleamine
• IDO 2,3-dioxygenase
• IL-10 IL-10
• TGF transforming growth factor-b
• CD39 CD73
• the immune checkpoint inhibitor targets an immune checkpoint receptor selected from CTLA-4, PD-l, PD-L1, PD-l - PD-L1, and PD-l - PD-L2.
• the immune checkpoint inhibitor is selected from:
• nivolumab also known as "OPDIVO”; formerly designated 5C4, BMS-936558, MDX- 1106, or ONO-4538
• pembrolizumab also known as "KEYTRUDA”, lambrolizumab, and MK-3475.
• PDR001 Novartis; see WO 2015/112900
• MEDI-0680 AstraZeneca; AMP-514; see WO 2012/145493
• cemiplimab (REGN-2810) (Regeneron; see WO 2015/112800)
• JS001 TAIZHOU JUNSHI PHARMA; see Si-Yang Liu et al., J. Hematol. Oncol.
• MPDL3280A also known as RG7446, atezolizumab, and TECENTRIQ; US 8,217,149; see, also, Herbst et al. (2013) J Clin Oncol 3l(suppl):3000
• durvalumab IMFINZI; MEDI-4736; AstraZeneca; see WO 2011/066389
• avelumab Pfizer; MSB- 0010718C; BAVENCIO; see WO 2013/079174
• STI-1014 Sacrrento; see
• AACR Abstract 4606 (Apr 2016)); urelumab, PF-05082566, MEDI6469, TRX518, varlilumab, CP-870893, BMS-986016, MGA271, lirilumab, IPH2201, emactuzumab,
• INCB024360 galunisertib, ulocuplumab, BKT140, Bavituximab, CC-90002, bevacizumab, MNRP1685A, ipilimumab (YERVOY; U.S. Patent No. 6,984,720), MK- 1308 (Merck), AGEN-1884 (Agenus Inc.; WO 2016/196237), and tremelimumab (formerly ticilimumab, CP-675,206; AstraZeneca; see, e.g., WO 2000/037504 and Ribas, Update Cancer Ther. 2(3): 133-39 (2007)).
• the immune checkpoint inhibitor is selected from:
• nivolumab nivolumab, pembrolizumab, JS001, BGB-A317, INCSHR1210, TSR-042, GLS-010, STI- 1110, MGD013, IBI308, BMS-936559, atezolizumab, durvalumab, avelumab, STI-1014,
• the immune checkpoint inhibitor is selected from: Urelumab, PF-05082566, MEDI6469, TRX518, Varlilumab, CP-870893, Pembrolizumab (PD1), Nivolumab (PD1), Atezolizumab (formerly MPDL3280A) (PDL1), MEDI4736 (PD-L1), Avelumab (PD-L1), PDR001 (PD1), BMS-986016, MGA271, Lirilumab, IPH2201, Emactuzumab, INCB024360, Galunisertib,
• the immune checkpoint inhibitor is selected from:
• nivolumab nivolumab, ipilimumab, pembrolizumab, atezolizumab, durvalumab and avelumab.
• the immune checkpoint inhibitor is selected from:
• the additional anti-cancer agent is a STING agonist.
• the STING agonist can include cyclic di-nucleotides, such as cAMP, cGMP, and cGAMP as well as modified cyclic di-nucleotides that include one or more of the following modification features (2’-0/3’-0 linkage, phosphorothioate linkage, adenine and/or guanine analogue, 2’-OH modification (e.g., -OCFE or replacement, e.g., -F or N3). See, e.g., WO 2014/189805.
• the additional chemotherapeutic agent is an alkylating agent.
• Alkylating agents are so named because of their ability to alkylate many nucleophilic functional groups under conditions present in cells, including, but not limited to cancer cells.
• an alkylating agent includes, but is not limited to, Cisplatin, carboplatin, mechlorethamine, cyclophosphamide, chlorambucil, ifosfamide and/or oxaliplatin.
• alkylating agents can function by impairing cell function by forming covalent bonds with the amino, carboxyl, sulfhydryl, and phosphate groups in biologically important molecules or they can work by modifying a cell's DNA.
• an alkylating agent is a synthetic, semisynthetic or derivative.
• the additional chemotherapeutic agent is an anti- metabolite.
• Anti-metabolites masquerade as purines or pyrimidines, the building-blocks of DNA and in general, prevent these substances from becoming incorporated in to DNA during the "S" phase (of the cell cycle), stopping normal development and division.
• Anti metabolites can also affect RNA synthesis.
• an antimetabolite includes, but is not limited to azathioprine and/or mercaptopurine.
• an anti- metabolite is a synthetic, semisynthetic or derivative.
• the additional chemotherapeutic agent is a plant alkaloid and/or terpenoid.
• These alkaloids are derived from plants and block cell division by, in general, preventing microtubule function.
• a plant alkaloid and/or terpenoid is a vinca alkaloid, a podophyllotoxin and/or a taxane.
• Vinca alkaloids in general, bind to specific sites on tubulin, inhibiting the assembly of tubulin into microtubules, generally during the M phase of the cell cycle.
• a vinca alkaloid is derived, without limitation, from the Madagascar periwinkle, Catharanthus roseus (formerly known as Vinca rosea).
• a vinca alkaloid includes, without limitation, Vincristine, Vinblastine, Vinorelbine and/or Vindesine.
• a taxane includes, but is not limited, to Taxol, Paclitaxel and/or Docetaxel.
• a plant alkaloid or terpemoid is a synthetic, semisynthetic or derivative.
• a podophyllotoxin is, without limitation, an etoposide and/or teniposide.
• a taxane is, without limitation, docetaxel and/or ortataxel.
• a cancer therapeutic is a topoisomerase.
• Topoisomerases are essential enzymes that maintain the topology of DNA. Inhibition of type I or type II topoisomerases interferes with both transcription and replication of DNA by upsetting proper DNA supercoiling.
• a topoisomerase is, without limitation, a type I topoisomerase inhibitor or a type II topoisomerase inhibitor.
• a type I topoisomerase inhibitor is, without limitation, a camptothecin.
• a camptothecin is, without limitation, exatecan, irinotecan, lurtotecan, topotecan, BNP 1350, CKD 602, DB 67 (AR67) and/or ST 1481.
• a type II topoisomerase inhibitor is, without limitation, epipodophyllotoxin.
• an epipodophyllotoxin is, without limitation, an amsacrine, etoposid, etoposide phosphate and/or teniposide.
• a type II topoisomerase inhibitor is, without limitation, epipodophyllotoxin.
• an epipodophyllotoxin is, without limitation, an amsacrine, etoposid, etoposide phosphate and/or teniposide.
• topoisomerase is a synthetic, semisynthetic or derivative, including those found in nature such as, without limitation, epipodophyllotoxins, substances naturally occurring in the root of American May apple (Podophyllum peltatum).
• the additional chemotherapeutic agent is a stilbenoid.
• a stilbenoid includes, but is not limited to, Resveratrol, Piceatannol, Pinosylvin, Pterostilbene, Alpha- Viniferin, Ampel opsin A, Ampelopsin E,
• Diptoindonesin C Diptoindonesin F, Epsilon- Vinferin, Flexuosol A, Gnetin H,
• a stilbenoid is a synthetic, semisynthetic or derivative.
• the additional chemotherapeutic agent is a cytotoxic antibiotic.
• a cytotoxic antibiotic is, without limitation, an actinomycin, an anthracenedione, an anthracycline, thalidomide, dichloroacetic acid, nicotinic acid, 2- deoxyglucose and/or chlofazimine.
• an actinomycin is, without limitation, actinomycin D, bacitracin, colistin (polymyxin E) and/or polymyxin B.
• an antracenedione is, without limitation, mitoxantrone and/or pixantrone.
• an anthracycline is, without limitation, bleomycin, doxorubicin (Adriamycin), daunorubicin (daunomycin), epirubicin, idarubicin, mitomycin, plicamycin and/or valrubicin.
• a cytotoxic antibiotic is a synthetic, semisynthetic or derivative.
• the additional chemotherapeutic agent is selected from endostatin, angiogenin, angiostatin, chemokines, angioarrestin, angiostatin (plasminogen fragment), basement-membrane collagen-derived anti-angiogenic factors (tumstatin, canstatin, or arrestin), anti-angiogenic antithrombin III, signal transduction inhibitors, cartilage-derived inhibitor (CDI), CD59 complement fragment, fibronectin fragment, gro- beta, heparinases, heparin hexasaccharide fragment, human chorionic gonadotropin (hCG), interferon alpha/beta/gamma, interferon inducible protein (IP-10), interleukin- 12, kringle 5 (plasminogen fragment), metalloproteinase inhibitors (TIMPs), 2- methoxy estradiol, placental ribonuclease inhibitor, plasminogen activator inhibitor, platelet factor-4 (PF4), prolactin
• the additional chemotherapeutic agent is selected from abiraterone acetate, altretamine, anhydrovinblastine, auristatin, bexarotene, bicalutamide, BMS 184476, 2,3,4,5,6-pentafluoro-N-(3-fluoro-4-methoxyphenyl)benzene sulfonamide, bleomycin, N,N-dimethyl-L-valyl-L-valyl-N-methyl-L-valyl-L-proly-l-Lproline-t- butylamide, cachectin, cemadotin, chlorambucil, cyclophosphamide, 3',4'-didehydro-4'- deoxy-8'-norvin-caleukoblastine, docetaxol, doxetaxel, cyclophosphamide, carboplatin, carmustine, cisplatin, cryptophycin,
• the additional chemotherapeutic agent is platinum, cisplatin, carboplatin, oxaliplatin, mechlorethamine, cyclophosphamide, chlorambucil, azathioprine, mercaptopurine, vincristine, vinblastine, vinorelbine, vindesine, etoposide and teniposide, paclitaxel, docetaxel, irinotecan, topotecan, amsacrine, etoposide, etoposide phosphate, teniposide, 5-fluorouracil, leucovorin, methotrexate, gemcitabine, taxane, leucovorin, mitomycin C, tegafur-uracil, idarubicin, fludarabine, mitoxantrone, ifosfamide and doxorubicin.
• Additional agents include inhibitors of mTOR (mammalian target of rapamycin), including but not limited to rapamycin, everolimus, temsirolimus and deforolimus.
• the additional chemotherapeutic agent can be selected from those delineated in U.S. Patent 7,927,613.
• the methods can further include administering one or both of: (i) one or more anti-fungal agents (e.g., selected from the group of bifonazole, butoconazole, clotrimazole, econazole, ketoconazole, luliconazole, miconazole, omoconazole, oxiconazole, sertaconazole, sulconazole, tioconazole, albaconazole, efmaconazole, epoziconazole, fluconazole, isavuconazole, itraconazole, posaconazole, propiconazole, ravusconazole, terconazole, voriconazole, abafungin, amorolfm, butenafme, naftifme, terbinafme, anidulafungin, caspofungin, micafungin, benzoic acid, ciclopirox, flucytosine, 5-
• troleandomycin telithromycin, spiramycin, aztreonam, furazolidone, nitrofurantoin, linezolid, posizolid, radezolid, torezolid, amoxicillin, ampicillin, azlocillin, carbenicillin, cloxacillin, dicloxacillin, flucloxacillin, mezlocillin, methicillin, nafcillin, oxacillin, penicillin G, penicillin V, piperacillin, penicillin G, temocillin, ticarcillin, amoxicillin, calvulanate, ampicillin, subbactam, piperacillin, tazobactam, ticarcillin, clavulanate, bacitracin, cobstin, polymyxin B, ciprofloxacin, enoxacin, gatifloxacin, gemifloxacin, levofloxacin, lomefloxacin,
• the second therapeutic agent or regimen is administered to the subject prior to contacting with or administering the chemical entity (e.g., about one hour prior, or about 6 hours prior, or about 12 hours prior, or about 24 hours prior, or about 48 hours prior, or about 1 week prior, or about 1 month prior).
• the chemical entity e.g., about one hour prior, or about 6 hours prior, or about 12 hours prior, or about 24 hours prior, or about 48 hours prior, or about 1 week prior, or about 1 month prior.
• the second therapeutic agent or regimen is administered to the subject at about the same time as contacting with or administering the chemical entity.
• the second therapeutic agent or regimen and the chemical entity are provided to the subject simultaneously in the same dosage form.
• the second therapeutic agent or regimen and the chemical entity are provided to the subject concurrently in separate dosage forms.
• the second therapeutic agent or regimen is N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl
• administered to the subject after contacting with or administering the chemical entity e.g., about one hour after, or about 6 hours after, or about 12 hours after, or about 24 hours after, or about 48 hours after, or about 1 week after, or about 1 month after.
• the methods described herein further include the step of identifying a subject (e.g., a patient) in need of such treatment (e.g., by way of biopsy, endoscopy, or other conventional method known in the art).
• a subject e.g., a patient
• the NLRP3 protein can serve as a biomarker for certain types of cancer.
• the chemical entities, methods, and compositions described herein can be administered to certain treatment-resistant patient populations (e.g., patients resistant to checkpoint inhibitors).
• the compounds of the present invention may be used in therapy.
• the present invention provides a combined preparation of a compound of the present invention, or a pharmaceutically acceptable salt thereof, and additional therapeutic agent(s) for simultaneous, separate or sequential use in therapy.
• the compounds of the invention may be used as a medicament.
• the compounds of the invention may be used for the manufacture of a medicament for the treatment of cancer.
• the compounds of the invention may be used for the manufacture of a medicament for modulating NLRP3 activity.
• the modulating comprises agonizing NLRP3.
• triethylamine can be interchanged with other bases, such as non-nucleophilic bases (e.g. diisopropylamine, 1,8- diazabicycloundec-7-ene, 2,6-di-tert-butylpyridine, or tetrabutylphosphazene).
• bases such as non-nucleophilic bases (e.g. diisopropylamine, 1,8- diazabicycloundec-7-ene, 2,6-di-tert-butylpyridine, or tetrabutylphosphazene).
• CD3OD methanol-
• CEEReCb methyltrioxorhenium
• DIEA A, A-diethyl isopropyl amine
• HC1 hydrogen chloride (usually as a solution)
• H2O2 hydrogen peroxide
• HATU l-[Bis(dimethylamino)methylene]-lH-l,2,3-triazolo[4,5-b]pyridinium 3- oxide hexafluorophosphate
• K2CO3 potassium carbonate
• K2HPO4 potassium phosphate, dibasic
• L1BH4 lithium borohydride
• m-CPBA meta-chloroperoxybenzoic acid
• MTO methyltrioxorhenium
• NaHCCb sodium hydrogen carbonate
• Na 2 S04 sodium sulfate
• nm nanometer
• PdCl 2 (PPh3) 2 bis(triphenylphosphine)palladium (II) dichloride
• POCh phosphorous oxychloride
• TosMIC toluenesulfonylmethyl isocyanide
• TsCl para -toluenesulfonyl chloride
• the compounds of the present invention can be prepared in a number of ways well known to one skilled in the art of organic synthesis.
• the compounds of the present invention can be synthesized using the methods described below, together with synthetic methods known in the art of synthetic organic chemistry, or variations thereon as appreciated by those skilled in the art. Preferred methods include, but are not limited to, those described below.
• the compounds of this invention may be prepared using the reactions and techniques described in this section (e.g., Schemes 1 to 11).
• Compound 10 may be prepared by a synthetic sequence outlined in Scheme 1.
• Indole 1 where the Hal group is a halide such as bromide, can be converted to intermediate 2 with a reagent such as ethyl 2-chloro-2-oxoacetate.
• a reagent such as ethyl 2-chloro-2-oxoacetate.
• Treatment of intermediate 2 with an appropriately functionalized hydrazine (NH2-NH-PG 1 ) in the presence of an acid, such as acetic acid provides intermediate 3, which can then be converted to intermediate 4 with a chlorinating reagent such as POCh.
• Addition of ammonia or an appropriately functionalized amine (NH2-PG 2 ) to intermediate 4 affords intermediate 5.
• the de-protection of intermediate 5 may be accomplished in several ways known to one skilled in the art.
• intermediate d 5 may be treated with a reagent such as TFA to afford intermediate 6.
• a reagent such as TFA
• Coupling between intermediate 6 and a coupling reagent 7 by the action of a suitable catalyst affords intermediate 8.
• this step may be accomplished by treating intermediate 6 with a suitable boronic ester, such as 3-(tetramethyl- l 3.2-dioxaborolan-2-yl)-///- pyrazole, in the presence of a catalyst such as_Pd(dppf)Cl2 to give intermediate 8.
• this step may be accomplished by treating intermediate 6 with a suitable heterocycle, such as pyrazole, in the presence of a copper catalyst, such as copper(I) iodide, and a ligand, such as N,N'-dimethylethylenediamine to give intermediate 8.
• a suitable heterocycle such as pyrazole
• copper catalyst such as copper(I) iodide
• a ligand such as N,N'-dimethylethylenediamine
• compound 10 can be prepared by treating intermediate 8 with an appropriately functionalized alkylating reagent (R 2 -X), where X is a leaving group such as a halide, in the presence of a base such as potassium carbonate.
• R 3 contains a protecting group, it may be removed at this stage under suitable conditions.
• R 3 -M was l-(tetrahydro-2H-pyran-2-yl)-5-(4,4,5,5-tetramethyl-l,3,2- dioxaborolan-2-yl)-lH-pyrazole
• the tetrahydropyran group can be removed by treatment with a reagent such as TFA.
• intermediate 6 may be functionalized first with an alkylating reagent R 2 -X to give compound lOa and then converted to compound 10 with a suitable coupling partner R 3 -M under the action of an catalyst as shown in Scheme 2.
• intermediate 8 can be accomplished by a two-step sequence as depicted in Scheme 3.
• intermediate 5 (prepared as in Scheme 1) can be coupled to a suitable coupling reagent R 3 -M by the action of a suitable catalyst to afford intermediate 11, which can then be de-protected with an acid such as TFA to afford intermediate 8.
• Analogs such as compounds l3a and 13b can be prepared according to the synthetic route illustrated in Scheme 4.
• Removal of the protecting group from 12 may be accomplished using suitable conditions to provide compound l3a.
• R 3 contains a protecting group, it may also be removed in this step.
• treatment with a reagent such as TFA may remove this group.
• Compound l3a may then be converted to the desired final product by treatment with the appropriate reagents.
• l3a may be converted to an amide by treatment with an appropriately-substituted carboxylic acid in the presence of a suitable coupling reagent, such as HATU, and a base, such as A A-di isopropyl ethyl amine.
• a suitable coupling reagent such as HATU
• a base such as A A-di isopropyl ethyl amine.
• compound l3a may by converted to an isoindolinone by treatment with a reagent such as methyl 2-(bromomethyl)benzoate, or an appropriately-substituted analog thereof, in the presence of a base, such as N.N- diisopropylethylamine.
• compound l3a may be alkylated by treatment with an appropriately-subsituted aldehyde or ketone in the presence of a suitable reducing agent, such as sodium triacetoxyborohydride.
• compound 13a may be converted to a sulfonamide by treatment with an appropriately-substituted sulfonyl chloride in the presence of a base, such as triethylamine.
• compound l3a may be converted to a urea by treatment with an appropriately-substituted isocyanate or carbamoyl chloride in the presence of a base, such as triethylamine.
• compound l3a may be converted to a carbamate by treatment with an appropriately- substituted chloroformate in the presence of a base, such as triethyl amine.
• Compound 22 may be prepared by a synthetic sequence outlined in Scheme 6.
• Intermediate 17 can be prepared by treating quinoline 16 with an appropriate
• halogenating reagent such as iodine
• a base such as sodium hydroxide
• Intermediate 17 can then be coupled to an appropriately substituted alkyne 18 under the action of a suitable catalyst, such as Pd(Ph3)4, to provide cyclized product 19.
• a suitable catalyst such as Pd(Ph3)4
• Further elaboration to compound 21 may be accomplished with a two-step sequence by first treating intermediate 19 with a suitable oxidant, such as /w-CPBA. to give oxide 20, which may be converted to compound 21 with a reagent, such as tosyl chloride, and an amine, such as ammonia.
• a suitable coupling partner by the action of a catalyst then provides compound 22.
• Analogs such as compound 29 can be prepared according to the synthetic route depicted in Scheme 7.
• amide bond formation between intermediate 23 and acid 24 in the presence of a suitable coupling reagent, such as HATU provides intermediate 25.
• Intermediate 25 can undergo cyclization reaction in the presence of suitable reagents such as C2CI6 and PPh 3 to provide intermediate 26.
• Further elaboration to compound 28 may be accomplished with a two-step sequence by first treating intermediate 26 with a suitable oxidant, such as / «.-CP BA. to give oxide 27, which was then converted to compound 28 with a reagent, such as tosyl chloride, and an amine, such as ammonia.
• Cross-coupling reaction between compound 28 with a suitable coupling partner by the action of a catalyst then provides compound 29.
• Analogs such as compound 33 can be prepared according to the synthetic route depicted in Scheme 8.
• intermediate 25 (prepared as shown in Scheme 7) can be converted to intermediate 30 with a suitable reagent, such as Lawesson’s reagent, in the presence of a base, such as pyridine.
• a suitable reagent such as Lawesson’s reagent
• a base such as pyridine
• Further elaboration to compound 32 may be accomplished with a two-step sequence by first treating compound 30 with a suitable oxidant, such as / «-CP BA. to give oxide 31, which may be converted to compound 32 with a reagent, such as tosyl chloride, and an amine, such as ammonia.
• Cross-coupling reaction between compound 32 with a suitable coupling partner by the action of a catalyst then provides compound 33.
• WO2013/045400 may be protected with a suitable protecting group, such as PMB, to provide intermediate 35.
• Intermediate 35 may then be converted to intermediate 36 with a chlorinating reagent such as POCb.
• a chlorinating reagent such as POCb.
• intermediate 37 functionalized amine (NFh-PG 2 ) to intermediate 36 affords intermediate 37.
• the de- protection of intermediate 37 may be accomplished in several ways known to one skilled in the art.
• compound 5 may be treated with a reagent such as TFA to afford intermediate 38.
• Compound 39 can be prepared by treating intermediate 38 with an appropriately functionalized alkylating reagent (R 2 -X), where X is a leaving group such as a halide, in the presence of a base such as potassium carbonate. Coupling between compound 39 and a coupling reagent by the action of a suitable catalyst affords compound 40.
• R 3 contains a protecting group, it may be removed at this stage using suitable conditions.
• R 3 -M was l-(tetrahydro- 2H-pyran-2-yl)-5-(4,4,5,5-tetramethyl-l,3,2-dioxaborolan-2-yl)-lH-pyrazole
• the tetrahydropyran group can be removed by treatment with a reagent such as TFA.
• Compound 52 may be prepared by a synthetic sequence outlined in Scheme 10.
• treatment of quinoline 41, where the Hal 1 group is a halide such as bromide, with a substituted amine 42, where R lb is H, a protecting group such as PMB, or R la provides compound 43.
• treatment of compound 43 with an iodinating reagent such as NIS provides compound 44, which can be coupled with an appropriately substituted alkyne 45 by the action of a suitable catalyst such as Pd(Ph3)2Cl2 and Cul to provide compound 46.
• the cyclization of compound 46 may be accomplished by the action of a base such as NaOH to give compound 47.
• Conversion to compound 48 may be accomplished by treating compound 47 with a suitable oxidant, such as /w-CPBA.
• this step may be accomplished by treating compound 49 with a suitable boronic ester, such as 3-(tetramethyl- l 3.2-dioxaborolan-2-yl)-///-pyra/ole. in the presence of a catalyst such as Pd(dppf)Cl2 to give compound 51.
• this step may be accomplished by treating compound 49 with a suitable heterocycle, such as pyrazole, in the presence of a copper catalyst, such as copper(I) iodide, and a ligand, such as N,N'-dimethyl- ethylenediamine to give compound 51.
• a suitable heterocycle such as pyrazole
• a copper catalyst such as copper(I) iodide
• a ligand such as N,N'-dimethyl- ethylenediamine
• Compound 61 may be prepared by a synthetic sequence outlined in Scheme 11.
• Scheme 11 treatment of quinoline 53, where Hal 1 group is a halide such as chloride, with an appropriately substituted hydrazine, such as (4-methoxybenzyl)hydrazine, provides compound 54.
• Conversion to compound 56 may be accomplished by treating compound 55 with a suitable oxidant, such as MTO.
• Compound 56 can then be further converted to compound 57 by a suitable reagent such as POCb.
• a suitable reagent such as POCb.
• Deprotection of compound 58 may be accomplished by the action of an acid, such as TFA, to provide compound 59.
• Coupling between compound 59 and a suitable coupling reagent by the action of a suitable catalyst affords compound 60.
• this step may be accomplished by treating compound 59 with a suitable boronic ester, such as 3- (tetramethyl- 1 3.2-dioxaborolan-2-yl)-///-pyra/ole. in the presence of a catalyst such as Pd(dppf)Ch to give compound 60.
• Compound 61 can be prepared by treating compound 60 with an appropriately functionalized alkylating reagent (R 2 -X), where X is a leaving group such as a halide, in the presence of a base such as potassium carbonate
• R 2 or R 3 contains a protecting group, it may be removed at this stage using suitable conditions.
• R 3 -M was l-(tetrahydro-2H-pyran-2-yl)-5-(4, 4,5,5- tetramethyl-l,3,2-dioxaborolan-2-yl)-lH-pyrazole, the tetrahydropyran group can be removed by treatment with a reagent such as TFA.
• Step 2 7-bromo-2-[(4-methoxyphenyl)methyl]-2H,4H,5H-pyrazolo[3,4-c]quinolin-4-one
• a solution of ethyl 2-(6-bromo-lH- indol-3-yl)-2-oxoacetate 1.7 g, 5.74 mmol, 1.00 equiv
• [(4-methoxyphenyl)methyl] hydrazine 1.007 g, 6.62 mmol, 1.15 equiv
• ethanol 25 mL
• acetic acid 3 mL
• Step 3 7-bromo-4-chloro-2-[(4-methoxyphenyl)methyl]-2H-pyrazolo[3,4-c]quinoline
• a solution of 7-bromo-2-[(4- methoxyphenyl)methyl]-2H,4H,5H-pyrazolo[3,4-c]quinolin-4-one 1.3 g, 3.38 mmol
• Step 8 3- [4-amino-7-( lH-py razol-3 -y l)-2H-py razolo [3 ,4-c] quinolin-2-y 1] propan- 1 -ol
• the crude product was purified by Prep-HPLC with the following conditions: Column, XBridge Shield RP18 OBD Column, 19 x 250mm, lOum; mobile phase, Water (10 mM NH4HCO3) and ACN (20.0% ACN up to 55.0% in 9 min);

Landscapes

• Chemical & Material Sciences (AREA)
• Organic Chemistry (AREA)
• Health & Medical Sciences (AREA)
• Medicinal Chemistry (AREA)
• Life Sciences & Earth Sciences (AREA)
• Pharmacology & Pharmacy (AREA)
• Veterinary Medicine (AREA)
• Public Health (AREA)
• General Health & Medical Sciences (AREA)
• Animal Behavior & Ethology (AREA)
• General Chemical & Material Sciences (AREA)
• Chemical Kinetics & Catalysis (AREA)
• Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
• Epidemiology (AREA)
• Immunology (AREA)
• Bioinformatics & Cheminformatics (AREA)
• Engineering & Computer Science (AREA)
• Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
• Nitrogen Condensed Heterocyclic Rings (AREA)
• Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
• Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
• Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
• Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
• Plural Heterocyclic Compounds (AREA)
• Hematology (AREA)
• Oncology (AREA)
• Endocrinology (AREA)
• Microbiology (AREA)
• Mycology (AREA)

Priority Applications (21)

Applications Claiming Priority (6)

Publications (1)

Family

ID=66677224

Family Applications (1)

Country Status (19)

Cited By (21)

Families Citing this family (1)

Citations (32)

Family Cites Families (18)

• 2019
  • 2019-04-24 PE PE2020001652A patent/PE20210160A1/es unknown
  • 2019-04-24 AU AU2019261582A patent/AU2019261582A1/en not_active Abandoned
  • 2019-04-24 SG SG11202010463TA patent/SG11202010463TA/en unknown
  • 2019-04-24 KR KR1020207033384A patent/KR102711180B1/ko active Active
  • 2019-04-24 US US17/049,612 patent/US12037344B2/en active Active
  • 2019-04-24 CN CN201980027881.7A patent/CN112074516A/zh active Pending
  • 2019-04-24 EP EP19727780.9A patent/EP3784670B1/en active Active
  • 2019-04-24 NZ NZ769136A patent/NZ769136A/en unknown
  • 2019-04-24 JP JP2020559472A patent/JP7351850B2/ja active Active
  • 2019-04-24 BR BR112020021539-2A patent/BR112020021539A2/pt not_active IP Right Cessation
  • 2019-04-24 CN CN202011468364.4A patent/CN112521387B/zh active Active
  • 2019-04-24 CA CA3097865A patent/CA3097865A1/en active Pending
  • 2019-04-24 MX MX2020011234A patent/MX2020011234A/es unknown
  • 2019-04-24 WO PCT/US2019/028823 patent/WO2019209896A1/en not_active Ceased
  • 2019-04-24 EP EP23211253.2A patent/EP4353235A3/en active Pending
  • 2019-04-24 ES ES19727780T patent/ES2971122T3/es active Active
  • 2019-04-25 TW TW108114491A patent/TW202014420A/zh unknown
• 2020
  • 2020-10-20 IL IL278173A patent/IL278173A/en unknown
  • 2020-10-21 CL CL2020002719A patent/CL2020002719A1/es unknown
  • 2020-10-21 CO CONC2021/0006672A patent/CO2021006672A2/es unknown
  • 2020-10-21 CO CONC2020/0013155A patent/CO2020013155A2/es unknown
  • 2020-11-24 ZA ZA2020/07307A patent/ZA202007307B/en unknown
• 2023
  • 2023-09-14 JP JP2023149057A patent/JP7660634B2/ja active Active

Patent Citations (35)

Non-Patent Citations (23)

Also Published As

Similar Documents

Legal Events